WO2023231452A1 - 含硝基芳香杂环基团的psma靶向放射性金属配合物及其制备 - Google Patents
含硝基芳香杂环基团的psma靶向放射性金属配合物及其制备 Download PDFInfo
- Publication number
- WO2023231452A1 WO2023231452A1 PCT/CN2023/075960 CN2023075960W WO2023231452A1 WO 2023231452 A1 WO2023231452 A1 WO 2023231452A1 CN 2023075960 W CN2023075960 W CN 2023075960W WO 2023231452 A1 WO2023231452 A1 WO 2023231452A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- psma
- add
- dissolve
- chelator
- lys
- Prior art date
Links
- 230000002285 radioactive effect Effects 0.000 title claims abstract description 87
- 238000002360 preparation method Methods 0.000 title claims abstract description 20
- 150000004696 coordination complex Chemical class 0.000 title claims abstract description 19
- 125000006615 aromatic heterocyclic group Chemical group 0.000 title claims abstract description 8
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 title claims abstract description 7
- 125000000623 heterocyclic group Chemical group 0.000 claims abstract description 53
- 239000002738 chelating agent Substances 0.000 claims abstract description 49
- -1 18F-AIF Chemical compound 0.000 claims abstract description 31
- 229910052751 metal Inorganic materials 0.000 claims abstract description 30
- 239000002184 metal Substances 0.000 claims abstract description 30
- WDLRUFUQRNWCPK-UHFFFAOYSA-N Tetraxetan Chemical compound OC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1 WDLRUFUQRNWCPK-UHFFFAOYSA-N 0.000 claims abstract description 11
- 125000005647 linker group Chemical group 0.000 claims abstract description 11
- JHALWMSZGCVVEM-UHFFFAOYSA-N 2-[4,7-bis(carboxymethyl)-1,4,7-triazonan-1-yl]acetic acid Chemical compound OC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CC1 JHALWMSZGCVVEM-UHFFFAOYSA-N 0.000 claims abstract description 5
- 239000000243 solution Substances 0.000 claims description 208
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 164
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 142
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 116
- 238000006243 chemical reaction Methods 0.000 claims description 100
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 96
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 claims description 81
- 150000001875 compounds Chemical class 0.000 claims description 75
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 claims description 70
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims description 63
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims description 63
- 239000007787 solid Substances 0.000 claims description 53
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 53
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims description 52
- 239000002904 solvent Substances 0.000 claims description 47
- 238000003756 stirring Methods 0.000 claims description 47
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 46
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 claims description 42
- 239000003446 ligand Substances 0.000 claims description 35
- 230000008685 targeting Effects 0.000 claims description 35
- 239000000706 filtrate Substances 0.000 claims description 32
- 239000012074 organic phase Substances 0.000 claims description 31
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 30
- 238000010898 silica gel chromatography Methods 0.000 claims description 27
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 claims description 25
- 229910021529 ammonia Inorganic materials 0.000 claims description 23
- 239000000203 mixture Substances 0.000 claims description 16
- XOYLJNJLGBYDTH-UHFFFAOYSA-M chlorogallium Chemical compound [Ga]Cl XOYLJNJLGBYDTH-UHFFFAOYSA-M 0.000 claims description 15
- 239000012071 phase Substances 0.000 claims description 15
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 14
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 14
- 239000000047 product Substances 0.000 claims description 13
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 12
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 11
- 229910052739 hydrogen Inorganic materials 0.000 claims description 11
- 239000001257 hydrogen Substances 0.000 claims description 11
- 238000000746 purification Methods 0.000 claims description 11
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims description 10
- 239000012298 atmosphere Substances 0.000 claims description 10
- 239000007974 sodium acetate buffer Substances 0.000 claims description 10
- 239000005909 Kieselgur Substances 0.000 claims description 7
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 7
- 239000003208 petroleum Substances 0.000 claims description 7
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 6
- CKGCFBNYQJDIGS-LBPRGKRZSA-N (2s)-2-azaniumyl-6-(phenylmethoxycarbonylamino)hexanoate Chemical compound [O-]C(=O)[C@@H]([NH3+])CCCCNC(=O)OCC1=CC=CC=C1 CKGCFBNYQJDIGS-LBPRGKRZSA-N 0.000 claims description 5
- LFEYMWCCUAOUKZ-FVGYRXGTSA-N [(2s)-1,5-bis[(2-methylpropan-2-yl)oxy]-1,5-dioxopentan-2-yl]azanium;chloride Chemical compound Cl.CC(C)(C)OC(=O)CC[C@H](N)C(=O)OC(C)(C)C LFEYMWCCUAOUKZ-FVGYRXGTSA-N 0.000 claims description 5
- 238000011894 semi-preparative HPLC Methods 0.000 claims description 5
- UCPYLLCMEDAXFR-UHFFFAOYSA-N triphosgene Chemical compound ClC(Cl)(Cl)OC(=O)OC(Cl)(Cl)Cl UCPYLLCMEDAXFR-UHFFFAOYSA-N 0.000 claims description 5
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims description 4
- 150000001412 amines Chemical class 0.000 claims description 4
- 230000001588 bifunctional effect Effects 0.000 claims description 4
- 238000010438 heat treatment Methods 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 4
- 229910052763 palladium Inorganic materials 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 150000001408 amides Chemical class 0.000 claims description 3
- 150000002148 esters Chemical class 0.000 claims description 3
- 229910052938 sodium sulfate Inorganic materials 0.000 claims description 3
- 235000011152 sodium sulphate Nutrition 0.000 claims description 3
- 239000012267 brine Substances 0.000 claims description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 2
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
- 229920006395 saturated elastomer Polymers 0.000 claims description 2
- 239000005416 organic matter Substances 0.000 claims 1
- 238000002372 labelling Methods 0.000 abstract description 44
- 206010028980 Neoplasm Diseases 0.000 abstract description 19
- 206010060862 Prostate cancer Diseases 0.000 abstract description 16
- 208000000236 Prostatic Neoplasms Diseases 0.000 abstract description 16
- 238000003745 diagnosis Methods 0.000 abstract description 10
- 239000012217 radiopharmaceutical Substances 0.000 abstract description 4
- 229940121896 radiopharmaceutical Drugs 0.000 abstract description 4
- 230000002799 radiopharmaceutical effect Effects 0.000 abstract description 4
- 238000001727 in vivo Methods 0.000 abstract description 2
- 230000000694 effects Effects 0.000 abstract 1
- 230000004060 metabolic process Effects 0.000 abstract 1
- 210000000056 organ Anatomy 0.000 abstract 1
- 230000002195 synergetic effect Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 56
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 48
- 238000004128 high performance liquid chromatography Methods 0.000 description 48
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 47
- 230000015572 biosynthetic process Effects 0.000 description 39
- 238000003786 synthesis reaction Methods 0.000 description 39
- 238000001228 spectrum Methods 0.000 description 33
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 27
- 238000000338 in vitro Methods 0.000 description 25
- 238000012790 confirmation Methods 0.000 description 24
- 239000002287 radioligand Substances 0.000 description 22
- 239000007821 HATU Substances 0.000 description 19
- 239000002243 precursor Substances 0.000 description 19
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 18
- 239000001632 sodium acetate Substances 0.000 description 18
- 235000017281 sodium acetate Nutrition 0.000 description 18
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 16
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
- 238000011534 incubation Methods 0.000 description 12
- QJUIUFGOTBRHKP-LQJZCPKCSA-N (2s)-2-[[(1s)-1-carboxy-5-[6-[3-[3-[[2-[[5-(2-carboxyethyl)-2-hydroxyphenyl]methyl-(carboxymethyl)amino]ethyl-(carboxymethyl)amino]methyl]-4-hydroxyphenyl]propanoylamino]hexanoylamino]pentyl]carbamoylamino]pentanedioic acid Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)N[C@H](C(O)=O)CCCCNC(=O)CCCCCNC(=O)CCC1=CC=C(O)C(CN(CCN(CC(O)=O)CC=2C(=CC=C(CCC(O)=O)C=2)O)CC(O)=O)=C1 QJUIUFGOTBRHKP-LQJZCPKCSA-N 0.000 description 11
- GYHNNYVSQQEPJS-UHFFFAOYSA-N Gallium Chemical compound [Ga] GYHNNYVSQQEPJS-UHFFFAOYSA-N 0.000 description 11
- 229910052733 gallium Inorganic materials 0.000 description 11
- 229910052732 germanium Inorganic materials 0.000 description 11
- GNPVGFCGXDBREM-UHFFFAOYSA-N germanium atom Chemical compound [Ge] GNPVGFCGXDBREM-UHFFFAOYSA-N 0.000 description 11
- 239000003550 marker Substances 0.000 description 11
- 102000005962 receptors Human genes 0.000 description 11
- 108020003175 receptors Proteins 0.000 description 11
- 230000009870 specific binding Effects 0.000 description 11
- PMZXXNPJQYDFJX-UHFFFAOYSA-N acetonitrile;2,2,2-trifluoroacetic acid Chemical compound CC#N.OC(=O)C(F)(F)F PMZXXNPJQYDFJX-UHFFFAOYSA-N 0.000 description 10
- 239000012043 crude product Substances 0.000 description 10
- 239000000284 extract Substances 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 8
- 239000013592 cell lysate Substances 0.000 description 8
- 239000003921 oil Substances 0.000 description 8
- 230000004700 cellular uptake Effects 0.000 description 7
- 239000012141 concentrate Substances 0.000 description 7
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 7
- 210000002307 prostate Anatomy 0.000 description 7
- GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 description 6
- XXMFJKNOJSDQBM-UHFFFAOYSA-N 2,2,2-trifluoroacetic acid;hydrate Chemical compound [OH3+].[O-]C(=O)C(F)(F)F XXMFJKNOJSDQBM-UHFFFAOYSA-N 0.000 description 6
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 6
- 229940125904 compound 1 Drugs 0.000 description 6
- 229940125758 compound 15 Drugs 0.000 description 6
- 229940125898 compound 5 Drugs 0.000 description 6
- 239000008367 deionised water Substances 0.000 description 6
- 229910021641 deionized water Inorganic materials 0.000 description 6
- 238000010586 diagram Methods 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 239000011259 mixed solution Substances 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- 238000004237 preparative chromatography Methods 0.000 description 6
- 238000000926 separation method Methods 0.000 description 6
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 5
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 5
- 229940125773 compound 10 Drugs 0.000 description 5
- 229940125797 compound 12 Drugs 0.000 description 5
- 229940126543 compound 14 Drugs 0.000 description 5
- 229940125782 compound 2 Drugs 0.000 description 5
- 238000004821 distillation Methods 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 238000003384 imaging method Methods 0.000 description 5
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 5
- 230000014759 maintenance of location Effects 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 239000006285 cell suspension Substances 0.000 description 4
- 239000003960 organic solvent Substances 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 3
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 101710181478 Envelope glycoprotein GP350 Proteins 0.000 description 3
- 230000027455 binding Effects 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 238000002405 diagnostic procedure Methods 0.000 description 3
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 238000012879 PET imaging Methods 0.000 description 2
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 2
- 102000007066 Prostate-Specific Antigen Human genes 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 229940126214 compound 3 Drugs 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- QEWYKACRFQMRMB-UHFFFAOYSA-N fluoroacetic acid Chemical compound OC(=O)CF QEWYKACRFQMRMB-UHFFFAOYSA-N 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000002390 rotary evaporation Methods 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 238000002626 targeted therapy Methods 0.000 description 2
- 229940126585 therapeutic drug Drugs 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- SJVFAHZPLIXNDH-QFIPXVFZSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-phenylpropanoic acid Chemical compound C([C@@H](C(=O)O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21)C1=CC=CC=C1 SJVFAHZPLIXNDH-QFIPXVFZSA-N 0.000 description 1
- ARXFMTURSPNMGH-VIFPVBQESA-N (2s)-2-amino-3-[4-(carboxymethoxy)phenyl]propanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=C(OCC(O)=O)C=C1 ARXFMTURSPNMGH-VIFPVBQESA-N 0.000 description 1
- RRONHWAVOYADJL-HNNXBMFYSA-N (2s)-3-phenyl-2-(phenylmethoxycarbonylamino)propanoic acid Chemical compound C([C@@H](C(=O)O)NC(=O)OCC=1C=CC=CC=1)C1=CC=CC=C1 RRONHWAVOYADJL-HNNXBMFYSA-N 0.000 description 1
- GOPWHXPXSPIIQZ-FQEVSTJZSA-N (4s)-4-(9h-fluoren-9-ylmethoxycarbonylamino)-5-[(2-methylpropan-2-yl)oxy]-5-oxopentanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CCC(O)=O)C(=O)OC(C)(C)C)C3=CC=CC=C3C2=C1 GOPWHXPXSPIIQZ-FQEVSTJZSA-N 0.000 description 1
- UVNPEUJXKZFWSJ-LMTQTHQJSA-N (R)-N-[(4S)-8-[6-amino-5-[(3,3-difluoro-2-oxo-1H-pyrrolo[2,3-b]pyridin-4-yl)sulfanyl]pyrazin-2-yl]-2-oxa-8-azaspiro[4.5]decan-4-yl]-2-methylpropane-2-sulfinamide Chemical compound CC(C)(C)[S@@](=O)N[C@@H]1COCC11CCN(CC1)c1cnc(Sc2ccnc3NC(=O)C(F)(F)c23)c(N)n1 UVNPEUJXKZFWSJ-LMTQTHQJSA-N 0.000 description 1
- CYMADHGOEXFBSX-UHFFFAOYSA-N 1,4,7,10-tetrazacyclododecane-1,4,7,10-tetracarboxylic acid Chemical compound OC(=O)N1CCN(C(O)=O)CCN(C(O)=O)CCN(C(O)=O)CC1 CYMADHGOEXFBSX-UHFFFAOYSA-N 0.000 description 1
- OAIJKWSKSXCMOI-UHFFFAOYSA-N 2-[4,10-bis(carboxymethyl)-7-(1,3-dicarboxypropyl)-1,4,7,10-tetrazacyclododec-1-yl]pentanedioic acid Chemical compound C1CN(CCN(CCN(CCN1CC(=O)O)C(CCC(=O)O)C(=O)O)CC(=O)O)C(CCC(=O)O)C(=O)O OAIJKWSKSXCMOI-UHFFFAOYSA-N 0.000 description 1
- YZEUHQHUFTYLPH-UHFFFAOYSA-N 2-nitroimidazole Chemical compound [O-][N+](=O)C1=NC=CN1 YZEUHQHUFTYLPH-UHFFFAOYSA-N 0.000 description 1
- QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 description 1
- WDBQJSCPCGTAFG-QHCPKHFHSA-N 4,4-difluoro-N-[(1S)-3-[4-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)piperidin-1-yl]-1-pyridin-3-ylpropyl]cyclohexane-1-carboxamide Chemical compound FC1(CCC(CC1)C(=O)N[C@@H](CCN1CCC(CC1)N1C(=NN=C1C)C(C)C)C=1C=NC=CC=1)F WDBQJSCPCGTAFG-QHCPKHFHSA-N 0.000 description 1
- BWGRDBSNKQABCB-UHFFFAOYSA-N 4,4-difluoro-N-[3-[3-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl]-1-thiophen-2-ylpropyl]cyclohexane-1-carboxamide Chemical compound CC(C)C1=NN=C(C)N1C1CC2CCC(C1)N2CCC(NC(=O)C1CCC(F)(F)CC1)C1=CC=CS1 BWGRDBSNKQABCB-UHFFFAOYSA-N 0.000 description 1
- KZAWZGLXGKYAGG-UHFFFAOYSA-N 6-amino-2-phenylmethoxycarbonylhexanoic acid Chemical compound NCCCCC(C(O)=O)C(=O)OCC1=CC=CC=C1 KZAWZGLXGKYAGG-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 102000006306 Antigen Receptors Human genes 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 208000007433 Lymphatic Metastasis Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 206010027452 Metastases to bone Diseases 0.000 description 1
- 206010027459 Metastases to lymph nodes Diseases 0.000 description 1
- KWYHDKDOAIKMQN-UHFFFAOYSA-N N,N,N',N'-tetramethylethylenediamine Chemical compound CN(C)CCN(C)C KWYHDKDOAIKMQN-UHFFFAOYSA-N 0.000 description 1
- LFZAGIJXANFPFN-UHFFFAOYSA-N N-[3-[4-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)piperidin-1-yl]-1-thiophen-2-ylpropyl]acetamide Chemical compound C(C)(C)C1=NN=C(N1C1CCN(CC1)CCC(C=1SC=CC=1)NC(C)=O)C LFZAGIJXANFPFN-UHFFFAOYSA-N 0.000 description 1
- 108010037516 PSMA-617 Proteins 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- NEHMKBQYUWJMIP-UHFFFAOYSA-N anhydrous methyl chloride Natural products ClC NEHMKBQYUWJMIP-UHFFFAOYSA-N 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- GPOGKMPXBDGPJH-UHFFFAOYSA-N butan-2-yl acetate hydrochloride Chemical compound Cl.CCC(C)OC(C)=O GPOGKMPXBDGPJH-UHFFFAOYSA-N 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 239000012295 chemical reaction liquid Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 229940125846 compound 25 Drugs 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000002059 diagnostic imaging Methods 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- IFQUWYZCAGRUJN-UHFFFAOYSA-N ethylenediaminediacetic acid Chemical compound OC(=O)CNCCNCC(O)=O IFQUWYZCAGRUJN-UHFFFAOYSA-N 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 229940050176 methyl chloride Drugs 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 238000009206 nuclear medicine Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 238000012636 positron electron tomography Methods 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000011472 radical prostatectomy Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- IOKGWQZQCNXXLD-UHFFFAOYSA-N tert-butyl n-(3-bromopropyl)carbamate Chemical compound CC(C)(C)OC(=O)NCCCBr IOKGWQZQCNXXLD-UHFFFAOYSA-N 0.000 description 1
- 150000003852 triazoles Chemical class 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 210000002229 urogenital system Anatomy 0.000 description 1
- JBHPLHATEXGMQR-LFWIOBPJSA-N vipivotide tetraxetan Chemical compound OC(=O)CC[C@H](NC(=O)N[C@@H](CCCCNC(=O)[C@H](CC1=CC=C2C=CC=CC2=C1)NC(=O)[C@H]1CC[C@H](CNC(=O)CN2CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC2)CC1)C(O)=O)C(O)=O JBHPLHATEXGMQR-LFWIOBPJSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/91—Nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0215—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing natural amino acids, forming a peptide bond via their side chain functional group, e.g. epsilon-Lys, gamma-Glu
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/02—Linear peptides containing at least one abnormal peptide link
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Definitions
- the invention relates to a PSMA targeted radioactive metal complex containing a nitroaromatic heterocyclic group and its preparation, and belongs to the technical fields of radiopharmaceuticals and medical imaging.
- Prostate Cancer is one of the most common malignant tumors of the male genitourinary system. Most patients with prostate cancer can be successfully treated by radical prostatectomy in the early stages of the disease. However, prostate cancer is highly prone to systemic metastasis, with 60% -80% of prostate cancer patients have already developed to an advanced stage and metastasized when they are diagnosed, so early diagnosis of prostate cancer is crucial.
- Existing routine diagnostic methods include screening based on serum Prostate Specific Antigen (PSA) levels, rectal prostate ultrasound, pelvic MRI examination, and prostate biopsy.
- PSA serum Prostate Specific Antigen
- conventional diagnostic methods are invasive and uncertain, and cannot achieve early and accurate diagnosis. Compared with conventional diagnostic methods, modern nuclear medicine has the characteristics of precision and trace amounts.
- Radionuclide-labeled probe molecules can specifically identify, And accumulate in the lesion site.
- diagnosis and treatment of tumor diseases can be collaboratively realized. It can achieve early and accurate diagnosis and treatment of cancer, and better provide patients with personalized diagnosis and treatment plans.
- PSMA Prostate Specific Membrane Antigen
- the Glu-Urea-Lys (GUL) structure is the key unit of PSMA targeting agents.
- a variety of PSMA-targeting molecular probes based on the Glu-Urea-Lys (GUL) structure have been developed, among which [ 68 Ga]Ga-HBED- CC-PSMA-11 ([ 68 Ga]Ga-PSMA-11) is currently the most widely used PSMA-targeted small molecule PET probe for PET imaging of prostate cancer. It was approved by the United States on December 1, 2020. Approved for marketing by the US Food and Drug Administration (FDA). The labeling of [ 68 Ga]Ga-HBED-CC-PSMA-11 is fast and efficient.
- the bifunctional chelator of HBED-CC-PSMA-11 ligand is HBED-CC, which is not suitable for treating metal nuclide labels (such as Lu-177) and cannot meet the needs of clinical radioactive targeted therapy.
- Benesova, M. et al. designed a new prostate cancer targeted radioactive drug [ 177 Lu]Lu-DOTA-PSMA-617 ([ 177 Lu]Lu-PSMA-617).
- This complex molecule maintains
- the original pharmacophore group GUL was replaced with DOTA as a bifunctional chelator, which can satisfy the labeling of 68 Ga and 177 Lu at the same time.
- the metal nuclide-labeled PSMA-617 prolonged tumor uptake and accelerated renal clearance, making this probe Needles are more suitable for clinical targeted therapy of prostate cancer.
- [ 177 Lu]Lu-PSMA-617 has been successfully approved by the FDA for the treatment of PSMA-positive prostate cancer.
- Prostate cancer is a solid tumor, and ideal PSMA-targeted radiopharmaceuticals should achieve high tumor uptake, low non-target tissue uptake, or rapid clearance of non-target tissues after injection.
- [ 68 Ga]Ga-PSMA-11 and [ 177 Lu]Lu-PSMA-617 have been approved by the FDA for marketing
- [ 68 Ga]Ga-PSMA-093 has also entered Phase II/III clinical studies, but both have certain shortcomings: [ 68 Ga]Ga-PSMA-11 and [ 68 Ga]Ga-PSMA-093 are limited to PET imaging diagnosis, while the tumor uptake of [ 177 Lu]Lu-PSMA-617 as a therapeutic drug needs to be improved.
- a new PSMA targeting radioactive metal ligand and its complex containing nitroaromatic heterocyclic groups are provided to improve the metabolic properties in the body, thereby enhancing the uptake and absorption of targeted molecules by tumors. Retention is an important way to find new radionuclide drugs with excellent properties for tumor diagnosis and treatment.
- One of the purposes of the present invention is to provide a novel PSMA-targeted radioactive metal ligand and its complex containing a nitroaromatic heterocyclic group, which exhibits high affinity and specificity for prostate-specific membrane antigen, and simultaneously has a nitroaromatic heterocyclic group.
- the introduction of aromatic heterocyclic groups can increase the retention of the complex in target tissues and enhance the uptake of targeting molecules by tumors. It is a promising compound targeting the prostate-specific membrane antigen receptor.
- a PSMA targeting radioactive metal ligand and its complex containing a nitro aromatic heterocyclic group its general formula is as shown in Formula I:
- Chelator 1 is a chelating group or a chelating structure that chelates radionuclides, selected from any of the following;
- M includes but is not limited to 68 Ga, 18 F-AlF, 177 Lu, 90 Y, 44 Sc, 225 Ac, 212 Pb, 213 Bi, etc.;
- R 1 is a nitroaromatic heterocyclic group, selected from any of the following:
- L 1 is the linking group between Chelator 1 and PSMA targeting group, selected from any of the following:
- L 2 is the connecting group between Chelator 1 and R 1 groups, selected from any of the following
- n takes an integer from 0 to 6.
- a PSMA targeting radioactive metal ligand and its complex containing a nitroaromatic heterocyclic group its general formula is as shown in Formula II:
- Chelator 2 is a chelating group or a chelating structure that chelates radionuclides, selected from any of the following:
- M includes but is not limited to 68 Ga, 18 F-AlF, 177 Lu, 90 Y, 44 Sc, 225 Ac, 212 Pb, 213 Bi, etc.;
- R 2 is a nitroaromatic heterocyclic group, selected from any of the following:
- L 3 is the linking group between Chelator 2 and PSMA targeting group, selected from any of the following:
- L 4 is the connecting group between Chelator 2 and R 2 groups, selected from any of the following:
- n takes an integer from 0 to 6.
- Another object of the present invention is to provide a method for preparing the above-mentioned PSMA targeted radioactive metal complex containing nitroaromatic heterocyclic groups.
- the colorless oily product was dissolved in tetrahydrofuran, and 10% Pd was added. /C, the mixture was stirred and reacted at room temperature in a hydrogen atmosphere. The resulting reaction solution was filtered through diatomaceous earth.
- the filtrate was evaporated under reduced pressure to remove the solvent and obtain the brown oily compound Lys(t-Bu)-CO-Glu(t-Bu ) 2 , dissolve Lys(t-Bu)-CO-Glu(t-Bu) 2 and Cbz-L 1 -NH 2 in anhydrous DMF, add 2-(7-azobenzotriazole under ice bath )-N,N,N',N'-tetramethylurea hexafluorophosphate and N,N'-diisopropylethylamine, react at room temperature, separate and purify overnight, and obtain a light yellow oily compound.
- the obtained Dissolve the light yellow oily compound in methanol, add Pd/C powder, and reduce it in a hydrogen atmosphere overnight to obtain NH 2 -L 1 -Lys(t-Bu)-CO-Glu(t-Bu) 2 ;
- the organic phase was collected and washed with Dry with aqueous sodium sulfate and filter to remove anhydrous sodium sulfate.
- step (3) Dissolve the labeled ligand obtained in step (3) into sodium acetate buffer solution, add [ 68 Ga]GaCl 3 or [ 177 Lu]LuCl 3 solution containing radionuclides to the solution, and react under heating conditions 5 -15min, the corresponding radioactive metal complex shown in structure I-2 is obtained.
- the colorless oily product was dissolved in tetrahydrofuran, and 10% Pd was added. /C, the mixture was stirred and reacted at room temperature in a hydrogen atmosphere. The resulting reaction solution was filtered through diatomaceous earth.
- the filtrate was evaporated under reduced pressure to remove the solvent and obtain the brown oily compound Lys(t-Bu)-CO-Glu(t- Bu) 2 , dissolve Lys(t-Bu)-CO-Glu(t-Bu) 2 and Cbz-L 3 -NH 2 in anhydrous DMF, add 2-(7-azobenzotriazole under ice bath Azole)-N,N,N',N'-tetramethylurea hexafluorophosphate and N,N'-diisopropylethylamine were reacted at room temperature overnight, separated and purified to obtain a light yellow oily compound, which was The obtained light yellow oily compound was dissolved in methanol, Pd/C powder was added, and reduced overnight in a hydrogen atmosphere to obtain NH 2 -L 3 -Lys(t-Bu)-CO-Glu(t-Bu) 2 ;
- step (3) Dissolve the labeled ligand obtained in step (3) into sodium acetate buffer solution, add [ 68 Ga]GaCl 3 or [ 177 Lu]LuCl 3 solution containing radionuclides to the solution, and react under heating conditions 5 -15min, the corresponding radioactive metal complex shown in structure II-2 is obtained.
- the novel PSMA-targeted radioactive metal ligand containing nitroaromatic heterocyclic groups of the present invention can label different radionuclides, and the prepared radioactive metal complex has high affinity and specificity for prostate-specific membrane antigen, and at the same time
- the introduction of nitroaromatic heterocyclic groups can increase the retention of the complex in target tissues and enhance the uptake of targeting molecules by tumors. It is a promising compound targeting prostate-specific membrane antigen receptors.
- Figure 1 is the radioactive HPLC spectrum of the labeling reaction solution of [ 68 Ga]Ga-HBED-CC-NI-PSMA prepared in Example 1 of the present invention
- Figure 2 is a radioactive HPLC spectrum of the labeling reaction solution of [ 68 Ga]Ga-AAZTA-NI-PSMA prepared in Example 2 of the present invention
- Figure 3 is a radioactive HPLC spectrum of the labeling reaction solution of [ 68 Ga]Ga-DOTA-NI-PSMA prepared in Example 3 of the present invention
- Figure 4 is the radioactive HPLC spectrum of the labeling reaction solution of [ 68 Ga]Ga-HBED-CC-NI-PSMA-11 prepared in Example 4 of the present invention
- Figure 5 is a radioactive HPLC spectrum of the labeling reaction solution of [ 68 Ga]Ga-AAZTA-NI-PSMA-11 prepared in Example 5 of the present invention
- Figure 6 is a radioactive HPLC spectrum of the labeling reaction solution of [ 68 Ga]Ga-DOTA-NI-PSMA-11 prepared in Example 6 of the present invention
- Figure 7 is the radioactive HPLC spectrum of the labeling reaction solution of [ 68 Ga]Ga-AAZTA-NI-PSMA-093 prepared in Example 7 of the present invention
- Figure 8 is the radioactive HPLC spectrum of the labeling reaction solution of [ 68 Ga]Ga-NI-HBED-CC-PSMA-11 prepared in Example 8 of the present invention
- Figure 9 is the radioactive HPLC spectrum of the labeling reaction solution of [ 68 Ga]Ga-NI-DOTAGA 2 -PSMA-11 prepared in Example 9 of the present invention.
- Figure 10 is a radioactive HPLC spectrum of the labeling reaction solution of [ 68 Ga]Ga-NI-HBED-CC-PSMA-093 prepared in Example 10 of the present invention
- Figure 11 is a radioactive HPLC spectrum of the labeling reaction solution of [ 68 Ga]Ga-NI-DOTAGA 2 -PSMA-093 prepared in Example 11 of the present invention
- Figure 12 shows the in vitro uptake of [ 68 Ga]Ga-AAZTA-NI-PSMA, [ 68 Ga]Ga-AAZTA-NI-PSMA-11 and [ 68 Ga]Ga by 22RV1-FOLH1-oe cells in Application Example 1 of the present invention.
- -Uptake-time graph of HBED-CC-PSMA-11 (n 3);
- Figure 14 shows the in vitro uptake of [ 68 Ga]Ga-AAZTA-NI-PSMA, [ 68 Ga]Ga-DOTA-NI-PSMA, and [ 68 Ga]Ga-HBED by 22RV1-FOLH1-oe cells in Application Example 2 of the present invention.
- -Uptake-time curves of CC-NI-PSMA and [ 68 Ga]Ga-HBED-CC-PSMA-11 (n 3);
- Figure 15 shows the in vitro 22RV1-FOLH1-oe cell uptake experimental analysis of [ 68 Ga]Ga-AAZTA-NI-PSMA, [ 68 Ga]Ga-DOTA-NI-PSMA, and [ 68 Ga]Ga in Application Example 2 of the present invention.
- -Specific binding diagram of HBED-CC-NI-PSMA and [ 68 Ga]Ga-HBED-CC-PSMA-11 and prostate-specific membrane antigen receptor (n 3);
- Figure 17 shows the in vitro 22RV1-FOLH1-oe cell uptake experimental analysis of [ 68 Ga]Ga-AAZTA-NI-PSMA-093 and [ 68 Ga]Ga-HBED-CC-PSMA-11 and prostate in Application Example 3 of the present invention.
- Figure 19 shows the in vitro 22RV1-FOLH1-oe cell uptake experimental analysis of [ 68 Ga]Ga-NI-HBED-CC-PSMA-11 and [ 68 Ga]Ga-HBED-CC-PSMA-11 in Application Example 4 of the present invention.
- [ 68 Ga]Ga-NI-HBED-CC-PSMA-093 and [ 68 Ga]Ga-HBED-CC-PSMA-093 specific binding diagram to prostate-specific membrane antigen receptor (n 3).
- the raw materials and reagents mentioned in the examples of the present invention are all conventional raw materials and reagents available on the market
- the testing methods used are all conventional methods used in the field
- the equipment and devices used are all conventional equipment in the field. and devices.
- Step 1 Synthesis of PSMA targeting radioligand HBED-CC-NI-PSMA containing nitroaromatic heterocyclic groups:
- the reaction solution was allowed to react at room temperature overnight.
- the reaction solution was washed with ethyl acetate.
- the ester and saturated brine were washed 5 times.
- the organic phase was collected and dried over anhydrous sodium sulfate.
- the anhydrous sodium sulfate was removed by filtration.
- the filtrate was concentrated by rotary evaporation under reduced pressure to precipitate a white solid compound 4 (362 mg, 0.50 mmol). Yield: 60 %;
- Dissolve compound 4 (500 mg, 0.69 mmol) in 2 mL of dichloromethane, add 2 mL of trifluoroacetic acid, and stir at room temperature for 30 minutes. The solvent is evaporated under reduced pressure to obtain an orange-yellow oily intermediate.
- the intermediate (358 mg, 0.54 mmol) is ) was dissolved in 4 mL of ultra-dry N,N-dimethylformamide.
- Add HATU (240 mg, 0.63 mmol) and DIPEA 134 mg, 1.04 mmol) in an ice bath. Stir in an ice bath for 30 minutes.
- the crude product was purified by high performance liquid chromatography.
- Semi-preparative chromatography column Eclipse XDB-C18, 5 ⁇ m, 9.4 ⁇ 250 mm. Separation conditions: Phase A. : 0.1% TFA water, Phase B: 0.1% TFA acetonitrile. Gradient: 0-12min, 5%-55%B; 12-13min, 55%-100%B; 13-16min, 100%B; 16-17min, 100%-5%B; 17-20min, 5%B , flow rate: 4mL/min, UV: 280nm, the target component is freeze-dried to obtain the white solid compound HBED-CC-NI-PSMA;
- Step 2 68 Ga labeling of PSMA targeting radioligand HBED-CC-NI-PSMA containing nitroaromatic heterocyclic groups:
- the 68 Ga marker route is as follows:
- HBED-CC-NI-PSMA Dissolve the HBED-CC-NI-PSMA obtained in step 1 in dimethyl sulfoxide to prepare a 1 ⁇ g/ ⁇ L precursor solution. Put 4 ⁇ L of the precursor solution into a 10 mL vial, add 135 ⁇ L of 3M sodium acetate solution, and use 6 mL of the precursor solution. Elute the germanium gallium generator (iThemba) with 0.6M high-purity hydrochloric acid solution to obtain [ 68 Ga]GaCl 3 hydrochloric acid solution. Take 300 ⁇ L and add it to the radioactive ligand sodium acetate mixed solution. After mixing evenly, react at 50°C. 10 minutes, cooled to room temperature, and measured its radiochemical purity using high-performance liquid chromatography with a radioactive detector, and obtained [ 68 Ga]Ga-HBED-CC-NI-PSMA with a radiochemical yield greater than 98%.
- Step 1 Synthesis of PSMA-targeting radioligand AAZTA-NI-PSMA containing nitroaromatic heterocyclic groups
- AAZTA (41 mg, 0.06 mmol) was dissolved To 2 mL of ultra-dry N,N-dimethylformamide, add HATU (27.4 mg, 0.07 mmol) and DIPEA (15.51 mg, 0.12 mmol) in an ice bath, stir for 30 minutes in an ice bath, and dissolve in 2 mL of ultra-dry N , The yellow oily intermediate of N-dimethylformamide (61.9 mg, 0.07 mmol) was added to the above reaction solution, and the reaction was carried out at room temperature overnight. The reaction solution was washed 5 times with ethyl acetate and saturated brine, and the organic phase was collected and washed with anhydrous sulfuric acid.
- phase B 0.1% TFA acetonitrile; gradient: 0-16min, 5%-41%B; 16-16.5min, 41%-100%B; 16.5-20min, 100%B; 20-20.5 min, 100%-5%B; 20.5-23min, 5%B, flow rate: 4mL/min, UV: 280nm, the target component is freeze-dried to obtain the white solid compound AAZTA-NI-PSMA;
- AAZTA-NI-PSMA The structure of AAZTA-NI-PSMA is confirmed: the purity is greater than 98% as determined by LC-MS;
- Step 2 68 Ga labeling of PSMA targeting radioligand AAZTA-NI-PSMA containing nitroaromatic heterocyclic groups
- the 68 Ga marker route is as follows:
- Step 1 Synthesis of PSMA targeting radioligand DOTA-NI-PSMA containing nitroaromatic heterocyclic groups:
- 1,4,7,10- Tri-tert-butyl tetraazacyclododecane-1,4,7,10-tetraacetate (DOTA, 34.34 mg, 0.06 mmol) was dissolved in 2 mL of ultra-dry N,N-dimethylformamide under ice bath Add HATU (29.66 mg, 0.08 mmol) and DIPEA (15.51 mg, 0.12 mmol), stir in an ice bath for 30 minutes, and dissolve the yellow oily intermediate (50 mg, 0.05 mmol) in 2 mL of ultra-dry N,N-dimethylformamide. ) Add the above reaction solution and react at room temperature overnight. The reaction solution is washed 5 times with ethyl acetate and saturated brine.
- the organic phase is collected and dried over anhydrous sodium sulfate, filtered, and the anhydrous sodium sulfate is removed. The filtrate is evaporated under reduced pressure.
- the product, crude product was purified by high performance liquid chromatography, semi-preparative chromatography column: Eclipse XDB-C18, 5 ⁇ m, 9.4 ⁇ 250mm, separation conditions: phase A: 0.1% TFA water, phase B: 0.1% TFA acetonitrile.
- Step 2 68 Ga labeling of PSMA targeting radioligand DOTA-NI-PSMA containing nitroaromatic heterocyclic groups
- the 68 Ga marker route is as follows:
- Step 1 Synthesis of PSMA-targeting radioligand HBED-CC-NI-PSMA-11 containing nitroaromatic heterocyclic groups
- Dissolve compound 4 500 mg, 0.69 mmol in 2 mL of dichloromethane, add 2 mL of trifluoroacetic acid, stir at room temperature for 30 minutes, evaporate under reduced pressure, and remove the solvent to obtain an orange-yellow oily intermediate.
- the orange-yellow oily intermediate 287 mg, 0.43 mmol was dissolved in 3 mL of ultra-dry N, N-dimethylformamide.
- Add HATU (183 mg, 0.48 mmol) and DIPEA 105 mg, 0.81 mmol) in an ice bath. Stir in the ice bath for 30 minutes.
- Dissolve compound 7 (305 mg, 0.24 mmol) in 5 mL of dichloromethane, add 1 mL of diethylamine, and stir at room temperature for 3 hours. Pressure evaporate and remove the solvent to obtain a yellow oily intermediate.
- Dissolve HBED-CC (33 mg, 0.05 mmol) in 2 mL of ultra-dry N,N-dimethylformamide, and add HATU (25 mg, 0.07 mmol) under ice bath.
- Step 2 68 Ga labeling of PSMA targeting radioligand HBED-CC-NI-PSMA-11 containing nitroaromatic heterocyclic groups
- the 68 Ga marker route is as follows:
- HBED-CC-NI-PSMA-11 obtained in step 1 in dimethyl sulfoxide to prepare a 1 ⁇ g/ ⁇ L precursor solution.
- Step 1 Synthesis of PSMA-targeting radioligand AAZTA-NI-PSMA-11 containing nitroaromatic heterocyclic groups
- Dissolve compound 7 (305 mg, 0.24 mmol) in 5 mL of dichloromethane, add 1 mL of diethylamine, stir at room temperature for 3 hours, evaporate under reduced pressure, and remove the solvent to obtain a yellow oily intermediate.
- AAZTA 33.57 mg, 0.05 mmol
- HATU 25 mg, 0.07 mmol
- DIPEA 13 mg, 0.10 mmol
- the crude product Purified by high performance liquid chromatography, semi-preparative chromatography column: Eclipse XDB-C18, 5 ⁇ m, 9.4 ⁇ 250 mm, separation conditions: phase A: 0.1% TFA water, phase B: 0.1% TFA acetonitrile. Gradient: 0-15min, 5%-100%B; 15-17min, 100%B; 17-17.5min, 100%-5%B; 17.5-20min, 5%B, flow rate: 4mL/min, UV: 280nm , the target component is freeze-dried to obtain the white solid compound AAZTA-NI-PSMA-11;
- Step 2 68 Ga labeling of PSMA targeting radioligand AAZTA-NI-PSMA-11 containing nitroaromatic heterocyclic groups:
- the 68 Ga marker route is as follows:
- Step 1 Synthesis of PSMA-targeting radioligand DOTA-NI-PSMA-11 containing nitroaromatic heterocyclic groups
- Dissolve compound 7 (305 mg, 0.24 mmol) in 5 mL of dichloromethane, add 1 mL of diethylamine, stir at room temperature for 3 hours, evaporate under reduced pressure, and remove the solvent to obtain a yellow oily intermediate.
- DOTA (29 mg, 0.05 mmol) Dissolve in 2 mL of ultra-dry N,N-dimethylformamide, add HATU (25 mg, 0.07 mmol) and DIPEA (13 mg, 0.10 mmol) in an ice bath, stir for 30 minutes in an ice bath, and dissolve in 2 mL of ultra-dry N.
- the yellow oily intermediate of N-dimethylformamide (50 mg, 0.05 mmol) was added to the above reaction solution and reacted at room temperature overnight.
- the reaction solution was washed 5 times with ethyl acetate and saturated brine.
- the product was deprotected with trifluoroacetic acid to obtain DOTA-NI-PSMA-11 crude product.
- the crude product was purified by high performance liquid chromatography.
- Semi-preparative chromatography column Eclipse XDB-C18, 5 ⁇ m, 9.4 ⁇ 250 mm. Separation conditions: Phase A. : 0.1% TFA water, phase B: 0.1% TFA acetonitrile, gradient: 0-15min, 5%-100%B; 15-17min, 100%B; 17-17.5min, 100%-5%B; 17.5-20min , 5% B, flow rate: 4mL/min, UV: 280nm, the target component was freeze-dried to obtain the white solid compound DOTA-NI-PSMA-11;
- Step 2 68 Ga labeling of PSMA targeting radioligand DOTA-NI-PSMA-11 containing nitroaromatic heterocyclic groups:
- the 68 Ga marker route is as follows:
- Step 1 Synthesis of PSMA-targeting radioligand AAZTA-NI-PSMA-093 containing nitroaromatic heterocyclic groups
- N-benzyloxycarbonyl-L-phenylalanine N-Cbz-L-Phe, 1.42g, 4.73mmol
- 1-hydroxybenzene at 0 degrees Celsius Triazole (HOBt, 872mg, 6.45mmol)
- DIPEA N,N-diisopropylethylamine
- DIPEA 1-ethyl-(3-dimethylaminopropyl) Carbodiimide hydrochloride
- EDCl 1-24g, 6.45mmol
- Dissolve compound 1 (2.10g, 4.30mmol) in 15mL N,N-dimethylformamide, add the above solution dropwise, and keep the reaction solution at room temperature Stir the reaction for 27 hours, add saturated sodium chloride solution and ethyl acetate for extraction, wash the organic phase three times with saturated sodium chloride solution, add anhydrous sodium sulfate,
- N-tert-butoxycarbonyl-L- Glutamic acid-5-methyl ester (530mg, 2.03mmol) was dissolved in 10mL N,N-dimethylformamide, and 1-hydroxybenzotriazole (HOBt, 410mg, 3.03mmol) was added at 0°C, N , N-diisopropylethylamine (DIPEA, 0.90mL, 704mg, 5.45mmol), 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDCl, 572mg, 2.99 mmol), dissolve the above yellow oily compound in 10 mL N,N-dimethylformamide, add the above solution dropwise, stir the reaction solution at room temperature for 26 hours, add saturated sodium chloride solution and ethyl acetate for extraction, and use the organic phase Wash three times with saturated sodium chloride solution, add anhydrous sodium sulfate, dry, filter, and concentrate the filtrate
- HATU '-Tetramethylurea hexafluorophosphate
- DIPEA N, N-diisopropylethylamine
- the reaction solution was stirred at room temperature for 27 hours. Add saturated sodium chloride solution and ethyl acetate, and extract. Use saturated sodium chloride solution for the organic phase.
- Step 2 68 Ga labeling of PSMA targeting radioligand AAZTA-NI-PSMA-093 containing nitroaromatic heterocyclic groups:
- the 68 Ga marker route is as follows:
- the dimethyl sulfoxide solution containing 20 nmol of the radioactive ligand AAZTA-NI-PSMA-093 was added to 150 ⁇ L of 3M sodium acetate buffer solution, and the germanium and gallium generator (iThemba laboratories, 740MBq, 20 mCi), add the obtained 300 ⁇ L [ 68 Ga]GaCl 3 hydrochloric acid solution to the sodium acetate buffer solution of the radioactive ligand, mix evenly, add water to dilute the total volume of the reaction solution to 500 ⁇ L, react at 50°C for 10 minutes, cool to room temperature, and use a tape to The labeling rate was measured by high-performance liquid chromatography (radio-HPLC) with a radioactivity detector, and [ 68 Ga]Ga-AAZTA-NI-PSMA-093 with a radiochemical purity greater than 95% was obtained.
- the germanium and gallium generator iThemba laboratories, 740MBq, 20 mCi
- Step 1 Synthesis of PSMA-targeting radioligand NI-HBED-CC-PSMA-11 containing nitroaromatic heterocyclic groups:
- HBED-CC 200 mg, 0.310 mmol
- 10 mL of anhydrous N,N-dimethylformamide 10 mL
- 2-(7-azabenzotriazole)- N,N,N,N'-tetramethylurea hexafluorophosphate HATU, 141 mg, 0.372mmol
- DIPEA N,N'-diisopropylethylamine
- compound 2 Dissolve in 2 mL of trifluoroacetic acid, stir for 1 hour and then distill under reduced pressure to obtain a white intermediate.
- Step 2 68 Ga labeling of PSMA targeting radioligand NI-HBED-CC-PSMA-11 containing nitroaromatic heterocyclic groups
- the 68 Ga marker route is as follows:
- Step 1 Synthesis of PSMA targeting radioligand NI-DOTAGA 2 -PSMA-11 containing nitroaromatic heterocyclic groups:
- DOTAGA 2 (200mg, 0.259mmol) in 10mL of anhydrous N,N-dimethylformamide, and add 2-(7-azabenzotriazole)-N to the solution in sequence under ice bath conditions.
- DIPEA N,N'-diisopropylethylamine
- DIPEA N,N'-diisopropylethylamine
- Step 2 68 Ga labeling of PSMA-targeting radioligand NI-DOTAGA 2 -PSMA-11 containing nitroaromatic heterocyclic groups:
- the 68 Ga marker route is as follows:
- Step 1 Synthesis of PSMA-targeting radioligand NI-HBED-CC-PSMA-093 containing nitroaromatic heterocyclic groups:
- Step 2 68 Ga labeling of PSMA targeting radioligand NI-HBED-CC-PSMA-093 containing nitroaromatic heterocyclic groups:
- the 68 Ga marker route is as follows:
- Step 1 Synthesis of PSMA targeting radioligand NI-DOTAGA 2 -PSMA-093 containing nitroaromatic heterocyclic groups:
- Step 2 68 Ga labeling of PSMA-targeting radioligand NI-DOTAGA 2 -PSMA-093 containing nitroaromatic heterocyclic groups:
- the 68 Ga marker route is as follows:
- 22RV1-FOLH1-oe cells were prepared into a cell suspension of 1 ⁇ 10 5 cells/mL, and 500 ⁇ L were inoculated into six 12-well plates. 37KBq of [ 68 Ga]Ga-AAZTA was added to each group of well plates.
- 22RV1-FOLH1-oe cells were prepared into a cell suspension of 1.5 ⁇ 10 5 cells/mL, and 500 ⁇ L were inoculated into six 12-well plates. 37KBq of [ 68 Ga]Ga-AAZTA was added to each group of well plates.
- 22RV1-FOLH1-oe cells interact with [ 68 Ga]Ga-AAZTA-NI-PSMA, [ 68 Ga]Ga-DOTA-NI-PSMA, and [ 68 Ga]Ga-HBED-CC-NI -PSMA and [ 68 Ga]Ga-HBED-CC-PSMA-11, with the prolongation of incubation time, the uptake first increased and then decreased, among which [ 68 Ga]Ga-HBED-CC-NI-PSMA increased at multiple time points.
- the cellular uptake is significantly higher than that of [ 68 Ga]Ga-HBED-CC-PSMA-11, which has been approved by the FDA.
- 22RV1-FOLH1-oe cells were prepared into a cell suspension of 1 ⁇ 10 5 cells/mL, and 500 ⁇ L were inoculated into three 12-well plates.
- 37KBq of [ 68 Ga]Ga-AAZTA was added to each group of well plates.
- - NI-PSMA-093 and [ 68 Ga]Ga-HBED-CC-PSMA-11 solutions, at 37°C, using PBS solution to terminate their uptake at 15, 30, 60, 90 and 120 minutes of incubation in each group use 1M NaOH to lyse the cells, use filter paper to absorb the cell lysate and put it into a plastic test tube to determine the radioactivity count; use an excess of unlabeled PSMA-11 at 60 minutes to block the cell uptake. After the incubation, use PBS solution to terminate its uptake. , use 1M NaOH to lyse the cells, use filter paper to absorb the cell lysate and put it into a plastic test tube to determine the radioactivity count.
- Figure 16 shows the in vitro uptake of [ 68 Ga]Ga-AAZTA-NI-PSMA-093 and [ 68 Ga]Ga-HBED-CC-PSMA-11 by 22RV1-FOLH1-oe cells in Application Example 2 of the present invention.
- Intake-time graph (n 3);
- Figure 19 shows the in vitro 22RV1-FOLH1-oe cell uptake experimental analysis of [ 68 Ga]Ga-HBED-CC-PSMA-11, [ 68 Ga]Ga-NI-HBED-CC- in Application Example 2 of the present invention.
- Specific binding diagram of PSMA-11, [ 68 Ga]Ga-HBED-CC-PSMA-093 and [ 68 Ga]Ga-NI-HBED-CC-PSMA-093 with prostate-specific membrane antigen receptor (n 3 ).
- the present invention contains a nitroaromatic heterocyclic group-targeting prostate-specific membrane antigen radioactive metal complex radioactive ligand, which contains different chelating agents and can chelate with almost all clinically used radioactive diagnostic and therapeutic metal nuclides, N, N 'Bis[2-hydroxy5-(carboxyethyl)benzyl]ethylenediamine-N,N'diacetic acid (HBED-CC) can coordinate with Ga 3+ with a high thermodynamic stability constant (logK ML : 38.5) The energy required is low, so the labeling of [ 68 Ga]Ga-HBED-CC is fast and efficient; 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetracarboxylic acid (DOTA ) and 2,2'-(4,10-biscarboxymethyl-1,4,7,10-tetraazacyclododecane-1,7-diyl)diglutaric acid (DOTAGA 2 ) and 2 ,2'
- the present invention contains a nitroaromatic heterocyclic group-targeting prostate-specific membrane antigen radioactive metal complex, contains a prostate-specific membrane antigen-targeting Lys-CO-Glu structure, and can fight against tumors that overexpress prostate-specific membrane antigen. Cell binding and internalization into cells together with prostate-specific membrane antigen receptor, the nitroaromatic heterocyclic group can enhance the retention of the complex in tumor cells.
- [ 68 Ga]Ga-NI-HBED-CC-PSMA-093, [ 68 Ga]Ga-AAZTA-NI-PSMA-093 and [ 68 Ga]Ga-HBED-CC-NI-PSMA are used in prostate-specific
- the uptake of membrane antigen-positive cells was significantly higher than that of [ 68 Ga]Ga-HBED-CC-PSMA-11, which has been approved by the FDA.
- the present invention contains a nitroaromatic heterocyclic group-targeting prostate-specific membrane antigen radioactive metal ligand, which can realize the labeling of a variety of radioactive diagnostic and therapeutic nuclides.
- the labeled imaging nuclides can be used as imaging radioactive metal ligands to obtain high Imaging contrast image; labeled therapeutic nuclide used as a radionuclide therapeutic drug can increase the retention of the drug at the tumor site and improve the therapeutic effect. Therefore, the prostate-specific prostate-specific drug containing nitroaromatic heterocyclic groups of the present invention
- Membrane antigen radioactive metal ligands can better realize the integration of diagnosis and treatment of prostate-specific membrane antigen receptor-positive tumors.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Optics & Photonics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Urology & Nephrology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
本发明公开了一种含硝基芳香杂环基团的PSMA靶向放射性金属配合物及其制备，属于放射性药物及医学影像技术领域；本发明的含硝基芳香杂环基团的PSMA靶向放射性金属配合物的通式如式Ⅰ和通式Ⅱ所示；其中R1和R2基为硝基芳香杂环基团；L2为R1基和L1之间的连接基团；L1为螯合剂和结构PSMA靶向结构的连接基团，L4为R2基和L3之间的连接基团；L3为螯合剂和结构PSMA靶向结构的连接基团，Chelator1和Chelator2为螯合剂或螯合结构。本发明首次将硝基杂环芳香基团和PSMA靶向基团同时连接于金属螯合剂上(HBED-CC、DOTA、DOTA(GA)2、NOTA、AAZTA等)，用于放射性金属核素例如68Ga、18F-AlF、177Lu、90Y、44Sc、225Ac、212Pb、213Bi等标记，有望通过硝基芳香杂环基团的体内协同作用提高前列腺癌对放射性金属标记物的摄取、加速非靶器官代谢，改善放射性药物对肿瘤诊断和治疗效果。
Description
本发明涉及一种含硝基芳香杂环基团的PSMA靶向放射性金属配合物及其制备，属于放射性药物及医学影像技术领域。
前列腺癌(Prostate Cancer，PCa)是男性泌尿生殖系统最常见的恶性肿瘤之一，大部分前列腺癌患者患病初期可通过根治性前列腺切除术成功治疗，但前列腺癌极易发生全身转移，60％-80％前列腺癌患者在被确诊时就已经发展到晚期并发生转移，所以前列腺癌的早期诊断至关重要。现有的常规诊断方式有基于血清中前列腺特异性抗原(Prostate Specific Antigen,PSA)水平的筛查、直肠前列腺超声、盆腔MRI检查以及前列腺穿刺组织活检等。但常规诊断方法具有入侵性，和不确定性，不能实现早期精准诊断，相较于常规诊断方式，现代核医学具有精确、微量的特点，放射性核素标记的探针分子能够特异性地识别，并积累于病灶部位，通过调整使用核素的种类，即可协同实现对肿瘤疾病的诊断和治疗，能够实现癌症早期精准诊疗，更好地为患者提供个性化诊疗方案。
前列腺特异性膜抗原(Prostate Specific Membrane Antigen,PSMA)目前是诊疗前列腺癌的理想靶点，其在前列腺癌细胞表面、淋巴节转移和骨转移中均存在选择性过表达，且在癌细胞中的表达量是正常组织的100-1000倍。PSMA几乎在前列腺癌的所有阶段都有表达，且表达量与疾病进程显著相关，可以为肿瘤分级和病理分期提供可靠依据。此外，PSMA的跨膜结构使其能够在与靶向分子结合后内化，有利于细胞内靶向药物高浓度的积累，这对肿瘤靶向治疗来说十分具有吸引力。
Glu-Urea-Lys(GUL)结构是PSMA靶向剂的关键单元，多种基于Glu-Urea-Lys(GUL)结构的靶向PSMA的分子探针被开发，其中[68Ga]Ga-HBED-CC-PSMA-11([68Ga]Ga-PSMA-11)是目前应用最为广泛的PSMA靶向小分子PET探针，用于前列腺癌的PET显像，已于2020年12月1日经美国食品药品监督局(U.S.Food and Drug Administration，FDA)批准上市。[68Ga]Ga-HBED-CC-PSMA-11的标记快速高效，其在体外细胞实验中对PSMA阳性表达细胞具有较高亲和性，在体内也表现出了较高的肿瘤摄取、较低的肝脏积累和较快的血液清除速率，但其主要通过泌尿系统代谢，肾脏和膀胱摄取较高。[68Ga]Ga-HBED-CC-PSMA-093([68Ga]Ga-PSMA-093)是继[68Ga]Ga-HBED-CC-PSMA-11之后另一个极具潜力的探针分子，由Kung,Hank F.等人于2017年公开(专利名称：UREA-BASED PROSTATE SPECIFIC MEMBRANE ANTIGEN(PSMA)INHIBITORS FOR IMAGING AND THERAPY，专利号：EP3397968B1)，目前已经进入临床II/III期研究。[68Ga]Ga-HBED-CC-PSMA-093保持了与[68Ga]Ga-HBED-CC-PSMA-11相同的药效基团和双功能螯合剂，通过增加O-(羧甲基)-l-酪氨酸作为连接基团，提高肿瘤摄取改善了[68Ga]Ga-HBED-CC-PSMA-11膀胱摄取高不利于前列腺癌原发灶，及局部复发灶显像表现欠佳等问题。
另一方面HBED-CC-PSMA-11配体的双功能螯合剂是HBED-CC，不适用于治疗金属核素标记(例如Lu-177)，无法满足临床放射性靶向治疗的需求。在此基础上，Benesova,M.等人设计出新型前列腺癌靶向放射性治疗药物[177Lu]Lu-DOTA-PSMA-617([177Lu]Lu-PSMA-617)，此配合物分子保持了原有的药效基团GUL，而将双功能螯合剂替换为DOTA，能够同时满足68Ga和177Lu的标记，金属核素标记的PSMA-617延长了肿瘤摄取并加快肾脏清除，使该探针更适用于临床前列腺癌的靶向治疗。2022年3月，[177Lu]Lu-PSMA-617已经成功获FDA批准用于PSMA阳性表达前列腺癌的治疗。
前列腺癌属于实体瘤，理想的PSMA靶向放射性药物应在注射后获得较高的肿瘤摄取、低非靶组织摄取或非靶组织快速清除。虽然[68Ga]Ga-PSMA-11和[177Lu]Lu-PSMA-617已被FDA批准上市，
[68Ga]Ga-PSMA-093也已经入II/III期临床研究，但均存在一定的缺点：[68Ga]Ga-PSMA-11和[68Ga]Ga-PSMA-093仅限于PET显像诊断，而[177Lu]Lu-PSMA-617作为治疗药物的肿瘤摄取量有待提高。
因此，通过化合物结构的修饰，提供一种含硝基芳香杂环基团的新型PSMA靶向放射性金属配体及其配合物，以便改善体内代谢性质，从而增强肿瘤对靶向分子的摄取量和滞留，是寻找优良性质的新型肿瘤诊疗核素药物的重要途径。
发明内容
本发明的目的之一在于提供一种含硝基芳香杂环基团的新型PSMA靶向放射性金属配体及其配合物，其表现出对前列腺特异型膜抗原的高亲和力和特异性，同时硝基芳香杂环基团的引入，能够增加配合物在靶组织内的滞留，增强肿瘤对靶向分子的摄取量，是颇具潜力的靶向前列腺特异性膜抗原受体化合物。
本发明的上述目的是通过以下技术方案达到的：
技术方案1：
一种含硝基芳香杂环基团的PSMA靶向放射性金属配体及其配合物，其通式如式Ⅰ所示：
其中，Chelator1为螯合基团或螯合放射性核素的螯合结构，选自以下任意一种；
其中，M包括但不限于68Ga、18F-AlF、177Lu、90Y、44Sc、225Ac、212Pb、213Bi等；
R1为硝基芳香杂环基团，选自以下任意一种：
L1为Chelator1和PSMA靶向基团之间的连接基团，选自以下任意一种：
L2为Chelator1和R1基团之间的连接基团，选自以下任意一种
其中n取0至6的整数。
技术方案2：
一种含硝基芳香杂环基团的PSMA靶向放射性金属配体及其配合物，其通式如式Ⅱ所示：
其中，Chelator2为螯合基团或螯合放射性核素的螯合结构，选自以下任意一种：
其中，M包括但不限于68Ga、18F-AlF、177Lu、90Y、44Sc、225Ac、212Pb、213Bi等；
R2为硝基芳香杂环基团，选自以下任意一种：
L3为Chelator2和PSMA靶向基团之间的连接基团，选自以下任意一种：
L4为Chelator2和R2基团之间的连接基团，选自以下任意一种：
其中，n取0至6的整数。
本发明的另一目的是提供上述含硝基芳香杂环基团的PSMA靶向放射性金属配合物制备方法。
本发明的上述目的是通过以下技术方案达到的：
技术方案1：
一种含硝基芳香杂环基团的PSMA靶向放射性金属配合物(如通式Ⅰ所示)的制备，其步骤如下：
(1)将三光气溶于二氯甲烷中，将溶于二氯甲烷的N(ε)-苄氧羰基-L-赖氨酸叔丁酯盐酸盐(H-Lys(Z)-Ot-Bu HCl)和三乙胺缓慢滴加至上述溶液中，将溶于二氯甲烷的L-谷氨酸二叔丁基酯盐酸盐和三乙胺缓慢滴加至上述溶液中，反应液室温下搅拌反应，减压蒸馏，使用硅胶柱色谱纯化(石油醚/乙酸乙酯＝1/1，v/v)，得到无色油状产物，将无色油状产物溶于四氢呋喃中，加入10％Pd/C，混合物于氢气气氛中室温下搅拌反应，所得反应液使用硅藻土抽滤，滤液减压旋蒸，除去溶剂，得到棕色油状化合物Lys(t-Bu)-CO-Glu(t-Bu)2，将Lys(t-Bu)-CO-Glu(t-Bu)2与Cbz-L1-NH2溶于无水DMF，冰浴下加入2-(7-偶氮苯并三氮唑)-N,N,N',N'-四甲基脲六氟磷酸酯和N,N’-二异丙基乙胺，室温反应，过夜分离，纯化，得到淡黄色油状化合物，将所得的淡黄色油状化合物溶于甲醇，加入Pd/C粉末，氢气气氛下还原，过夜，得到NH2-L1-Lys(t-Bu)-CO-Glu(t-Bu)2；
(2)将(S)-4-((((9H-芴-9-基)甲氧基)羰基)氨基)-5-(叔丁氧基)-5-氧代戊酸溶于超干N,N-二甲基甲酰胺中，冰浴下加入2-(7-偶氮苯并三氮唑)-N,N,N',N'-四甲基脲六氟磷酸酯和N,N’-二异丙基乙胺，冰浴搅拌，随后加入R1-L2-NH2，反应液于室温搅拌，过夜，反应液用乙酸乙酯和饱和食盐水洗涤，收集有机相并用无水硫酸钠干燥，过滤，除掉无水硫酸钠，滤液减压旋蒸，除去溶剂后，通过硅胶柱色谱纯化(二氯甲烷/甲醇/氨水，v/v/v＝25/1/0.1)，得到淡黄色固体，将得到的淡黄色固体溶于三氟乙酸中，室温搅拌，减压蒸馏，得到淡黄色固体化合，将得到淡黄色固体化合溶于超干N,N-二甲基甲酰胺中，冰浴下加入2-(7-偶氮苯并三氮唑)-N,N,N',N'-四甲基脲六氟磷酸酯和N,N’-二异丙基乙胺，冰浴搅拌，将溶于超干N,N-二甲基甲酰胺的NH2-L1-Lys(t-Bu)-CO-Glu(t-Bu)2加入上述反应液，室温反应，过夜，反应液用乙酸乙酯和饱和食盐水洗涤，收集有机相并用无水硫酸钠干燥，过滤，除掉无水硫酸钠，滤液减压旋蒸，除去溶剂，剩余物通过快速纯化色谱仪纯化(二氯甲烷/甲醇/氨水，v/v/v＝15/1/0.1)，得到淡黄色固体状化合物，将得到的淡黄色固体状化合物溶于二氯甲烷中，逐滴加入二乙胺，室温搅拌，减压旋蒸，除去溶剂，得到R1-L2-NH-L1-Lys(t-Bu)-CO-Glu(t-Bu)2；
(3)将螯合剂HBED-CC、AAZTA、DOTA或NOTA溶于无水DMF，冰浴下加入2-(7-偶氮苯并三氮唑)-N,N,N',N'-四甲基脲六氟磷酸酯和N,N’-二异丙基乙胺冰浴搅拌，随后加入步骤(2)所得的R1-L2-NH-L1-Lys(t-Bu)-CO-Glu(t-Bu)2，室温搅拌，过夜，经过硅胶柱色谱纯化，得到淡黄色油状液体R1-
L2-NH-L1(chelator1)-Lys(t-Bu)-CO-Glu(t-Bu)2，将得到的R1-L2-NH-L1(chelator1)-Lys(t-Bu)-CO-Glu(t-Bu)2溶于三氟乙酸，室温搅拌，减压蒸馏，除去溶剂，经半制备HPLC纯化，得到如结构Ⅰ-1所示的标记配体R1-L2-NH-L1(chelator1)-Lys-CO-Glu；
(4)将步骤(3)所得的标记配体溶于醋酸钠缓冲溶液，向溶液中加入[68Ga]GaCl3或[177Lu]LuCl3含有放射性核素的溶液，加热条件下，反应5-15min，得到相应的如结构Ⅰ-2所示的放射性金属配合物。
技术方案2：
一种含硝基芳香杂环基团的PSMA靶向放射性金属配合物(通式Ⅱ所示)的制备，其步骤如下：
(1)将三光气溶于二氯甲烷中，将溶于二氯甲烷的N(ε)-苄氧羰基-L-赖氨酸叔丁酯盐酸盐(H-Lys(Z)-Ot-Bu HCl)和三乙胺缓慢滴加至上述溶液中，将溶于二氯甲烷的L-谷氨酸二叔丁基酯盐酸盐和三乙胺缓慢滴加至上述溶液中，反应液室温下搅拌反应，减压蒸馏，使用硅胶柱色谱纯化(石油醚/乙酸乙酯＝1/1，v/v)，得到无色油状产物，将无色油状产物溶于四氢呋喃中，加入10％Pd/C，混合物于氢气气氛中室温下搅拌反应，，所得反应液使用硅藻土抽滤，滤液减压旋蒸，除去溶剂，得到棕色油状化合物Lys(t-Bu)-CO-Glu(t-Bu)2，将Lys(t-Bu)-CO-Glu(t-Bu)2与Cbz-L3-NH2溶于无水DMF，冰浴下加入2-(7-偶氮苯并三氮唑)-N,N,N',N'-四甲基脲六氟磷酸酯和N,N’-二异丙基乙胺，室温反应，过夜，分离，纯化，得到淡黄色油状化合物，将所得的淡黄色油状化合物溶于甲醇，加入Pd/C粉末，氢气气氛下还原过夜，得到NH2-L3-Lys(t-Bu)-CO-Glu(t-Bu)2；
(2)将螯合剂HBED-CC、AAZTA、DOTA或NOTA溶于无水DMF，冰浴下加入2-(7-偶氮苯并三氮唑)-N,N,N',N'-四甲基脲六氟磷酸酯和N,N’-二异丙基乙胺冰浴搅拌，随后加入R2-L4-NH2，反应液于室温搅拌，过夜，反应液用乙酸乙酯和饱和食盐水洗涤，收集有机相并用无水硫酸钠干燥，过滤，除掉无水硫酸钠，滤液减压旋蒸，除去溶剂后，通过硅胶柱色谱纯化(二氯甲烷/甲醇/氨水，v/v/v＝90/10/0.1)，得到淡黄色固体R2-L4-NH-chelator2，将所得的淡黄色固体R2-L4-NH-(chelator2)溶于无水DMF，冰浴下加入2-(7-偶氮苯并三氮唑)-N,N,N',N'-四甲基脲六氟磷酸酯和N,N’-二异丙基乙胺，冰浴搅拌，随后加入步骤(1)所得的NH2-L3-Lys(t-Bu)-CO-Glu(t-Bu)2，随后加入R2-L4-NH2，反应液于室温搅拌，过夜，反应液用乙酸乙酯和饱和食盐水洗涤，收集有机相并用无水硫酸钠干燥，过滤，除掉无水硫酸钠，滤液减压旋蒸，去除溶剂后，通过硅胶柱色谱纯化(二氯甲烷/甲醇/氨水，v/v/v＝90/10/0.1)，得到淡油状液体R2-L4-NH-chelator2-NH-L3-Lys(t-Bu)-CO-Glu(t-Bu)2，将得到的R2-L4-NH-chelator2-NH-L3-Lys(t-Bu)-CO-Glu(t-Bu)2溶于三氟乙酸，室温搅拌，减压蒸馏，除去溶剂，经半制备HPLC纯化，得到如结构Ⅱ-1所示的标记配体R2-L4-NH-chelator2-NH-L3-Lys-CO-Glu；
(4)将步骤(3)所得的标记配体溶于醋酸钠缓冲溶液，向溶液中加入[68Ga]GaCl3或[177Lu]LuCl3含有放射性核素的溶液，加热条件下，反应5-15min，得到相应的如结构Ⅱ-2所示的放射性金属配合物。
本发明的含硝基芳香杂环基团的新型PSMA靶向放射性金属配体，能够标记不同放射性核素，制备得到的放射性金属配合物对前列腺特异性膜抗原，具有高亲和力和特异性，同时硝基芳香杂环基团的引入，能够增加配合物在靶组织内的滞留，增强肿瘤对靶向分子的摄取量，是颇具潜力的靶向前列腺特异想膜抗原受体化合物。
下面通过附图和具体实施方式对本发明做进一步说明，但并不意味着对本发明保护范围的限制。
图1为本发明实施例1中制备的[68Ga]Ga-HBED-CC-NI-PSMA的标记反应液的放射性HPLC图谱；
图2为本发明实施例2中制备的[68Ga]Ga-AAZTA-NI-PSMA的标记反应液的放射性HPLC图谱；
图3为本发明实施例3中制备的[68Ga]Ga-DOTA-NI-PSMA的标记反应液的放射性HPLC图谱；
图4为本发明实施例4中制备的[68Ga]Ga-HBED-CC-NI-PSMA-11的标记反应液放射性HPLC图谱；
图5为本发明实施例5中制备的[68Ga]Ga-AAZTA-NI-PSMA-11的标记反应液的放射性HPLC图谱；
图6为本发明实施例6中制备的[68Ga]Ga-DOTA-NI-PSMA-11的标记反应液的放射性HPLC图谱；
图7为本发明实施例7中制备的[68Ga]Ga-AAZTA-NI-PSMA-093的标记反应液放射性HPLC图谱；
图8为本发明实施例8中制备的[68Ga]Ga-NI-HBED-CC-PSMA-11的标记反应液放射性HPLC图谱；
图9为本发明实施例9中制备的[68Ga]Ga-NI-DOTAGA2-PSMA-11的标记反应液放射性HPLC图谱；
图10为本发明实施例10中制备的[68Ga]Ga-NI-HBED-CC-PSMA-093的标记反应液的放射性HPLC图谱；
图11为本发明实施例11中制备的[68Ga]Ga-NI-DOTAGA2-PSMA-093的标记反应液的放射性HPLC图谱；
图12为本发明应用实施例1中，体外22RV1-FOLH1-oe细胞摄取[68Ga]Ga-AAZTA-NI-PSMA、[68Ga]Ga-AAZTA-NI-PSMA-11和[68Ga]Ga-HBED-CC-PSMA-11的摄取量-时间曲线图(n＝3)；
图13为本发明应用实施例1中，体外22RV1-FOLH1-oe细胞摄取实验分析[68Ga]Ga-AAZTA-NI-PSMA、[68Ga]Ga-AAZTA-NI-PSMA-11和[68Ga]Ga-HBED-CC-PSMA-11与前列腺特异型膜抗原受体的特异性结合图(n＝3)；
图14为本发明应用实施例2中，体外22RV1-FOLH1-oe细胞摄取[68Ga]Ga-AAZTA-NI-PSMA、[68Ga]Ga-DOTA-NI-PSMA、[68Ga]Ga-HBED-CC-NI-PSMA和[68Ga]Ga-HBED-CC-PSMA-11的摄取量-时间曲线图(n＝3)；
图15为本发明应用实施例2中，体外22RV1-FOLH1-oe细胞摄取实验分析[68Ga]Ga-AAZTA-NI-PSMA、[68Ga]Ga-DOTA-NI-PSMA、[68Ga]Ga-HBED-CC-NI-PSMA和[68Ga]Ga-HBED-CC-PSMA-11与前列腺特异型膜抗原受体的特异性结合图(n＝3)；
图16为本发明应用实施例3中，体外22RV1-FOLH1-oe细胞摄取[68Ga]Ga-AAZTA-NI-PSMA-093和[68Ga]Ga-HBED-CC-PSMA-11的摄取量-时间曲线图(n＝3)；
图17为本发明应用实施例3中，体外22RV1-FOLH1-oe细胞摄取实验分析[68Ga]Ga-AAZTA-NI-PSMA-093和[68Ga]Ga-HBED-CC-PSMA-11与前列腺特异型膜抗原受体的特异性结合图(n＝3)；
图18为本发明应用实施例4中，体外22RV1-FOLH1-oe细胞摄取[68Ga]Ga-NI-HBED-CC-PSMA-11、[68Ga]Ga-HBED-CC-PSMA-11、[68Ga]Ga-NI-HBED-CC-PSMA-093和[68Ga]Ga-HBED-CC-PSMA-093的摄取量-时间曲线图(n＝3)；
图19为本发明应用实施例4中，体外22RV1-FOLH1-oe细胞摄取实验分析[68Ga]Ga-NI-HBED-CC-PSMA-11、[68Ga]Ga-HBED-CC-PSMA-11、[68Ga]Ga-NI-HBED-CC-PSMA-093和[68Ga]Ga-HBED-CC-PSMA-093与前列腺特异型膜抗原受体的特异性结合图(n＝3)。
除非特别，本发明实施例中提到的原料和试剂均为市场上可购的常规原料和试剂，所用测试方法均为本领域所用的常规方法，所用的设备和装置均为本领域的常规设备和装置。
实施例1：[68Ga]Ga-HBED-CC-NI-PSMA的制备
步骤1：含有硝基芳香杂环基团的PSMA靶向放射性配体HBED-CC-NI-PSMA的合成：
合成路线如下：
具体包括以下步骤：
(1)化合物1的合成
将三光气(1.20g，4.03mmol)溶于10mL二氯甲烷中，于-20摄氏度下搅拌20分钟，将溶于75mL二氯甲烷的N(ε)-苄氧羰基-L-赖氨酸叔丁酯盐酸盐(H-Lys(Z)-Ot-Bu HCl，4.47g，12.0mmol)和三乙胺(2.80mL，2.04g，20.2mmol)缓慢滴加至上述溶液中，将溶于50mL二氯甲烷的L-谷氨酸二叔丁基酯盐酸盐(Glu-Ot-Bu(Ot-Bu)HCl，2.90g，9.83mmol)和三乙胺(2.80mL，2.04g，20.2mmol)缓慢滴加至上述溶液中，反应液室温下搅拌反应18小时，减压蒸馏，使用硅胶柱色谱纯化(石油醚/乙酸乙酯＝1/1，v/v)，得到无色油状产物(3.04g，4.89mmol)，产率：48.9％。将无色油状产物(2.25g，3.62mmol)溶于20mL四氢呋喃中，加入10％Pd/C(192mg)，混合物于氢气气氛中室温下搅拌反应12小时，所得反应液使用硅藻土抽滤，滤液减压旋蒸，除去溶剂，得到棕色油状化合物1(1.20g，2.46mmol)，产率：68.0％；
化合物1的结构确认：
HRMS C24H46N3O7[M+H]+理论分子量488.3330,实测分子量488.3334；
1HNMR(600MHz,CDCl3)δ:5.36(t,2H,J＝7.8Hz),4.30(dq,2H,J＝7.5,5.3Hz),2.65(t,2H,J＝6.9Hz),2.33-2.20(m,2H),2.06-2.00(m,2H),1.85-1.77(m,1H),1.73(ddt,1H,J＝13.5,10.4,5.3Hz),1.67(s,2H),1.61-1.53(m,1H),1.42(d,18H,J＝0.5Hz),1.39(s,9H),1.33-1.26(m,1H)；
(2)化合物2的合成
将2-硝基咪唑(1.14g，10.09mmol)溶于15mL超干N,N-二甲基甲酰胺，加入无水碳酸钾(4.89g，35.38mmol)，室温搅拌30分钟，将溶于超干N,N-二甲基甲酰胺(10mL)的N-(3-溴丙基)氨基甲酸叔丁酯(3.57g，14.99mmol)加入上述反应液。反应液室温搅拌过夜后用硅藻土抽滤，滤液通过减压旋蒸除掉大部分溶剂，剩余物用乙酸乙酯和饱和食盐水洗涤，收集有机相并用无水硫酸钠干燥，减压旋蒸，除去溶剂，剩余物通过硅胶柱色谱纯化(石油醚/乙酸乙酯，v/v＝1/1)，得到黄绿色油状物2(2.36g，8.74mmol)，产率：87％；
化合物2的结构确认：
HRMS C11H19N4O4[M+H]+理论分子量271.1400，实测分子量271.1408；
1H NMR(600MHz,CDCl3)δ7.27(s,1H),7.14(s,1H),4.75(s,1H),4.46(t,J＝7.0Hz,2H),3.20(t,J＝6.2Hz,2H),2.08-2.01(m,2H),1.44(s,9H)；
(3)化合物3的合成
将化合物2(432mg，1.60mmol)溶于4mL三氟乙酸中，室温搅拌30分钟，通过减压旋蒸除溶剂，得到白色固体状中间体，将(S)-4-((((9H-芴-9-基)甲氧基)羰基)氨基)-5-(叔丁氧基)-5-氧代戊酸(1.5g，3.53mmol)溶于10mL超干N,N-二甲基甲酰胺中，冰浴下加入2-(7-偶氮苯并三氮唑)-N,N,N',N'-四甲基脲六氟磷酸酯(HATU，1.61g，4.23mmol)和N,N’-二异丙基乙胺(DIPEA，547mg，4.23mmol)，冰浴搅拌25分钟，随后加入上述白色固体状中间体(603mg，3.55mmol)，反应液于室温搅拌过夜，反应液用乙酸乙酯和饱和食盐水洗涤5次，收集有机相并用无水硫酸钠干燥，过滤，除掉无水硫酸钠，滤液减压旋蒸，除去溶剂后，通过硅胶柱色谱纯化(二氯甲烷/甲醇/氨水，v/v/v＝25/1/0.1)，得到淡黄色固体3(1.5g，2.60mmol)，产率：74％；
化合物3的结构确认：
HRMS C30H36N5O7[M+H]+理论分子量578.2609，实测分子量578.2609；
1H NMR(400MHz,CDCl3)δ7.76(d,J＝7.6Hz,2H),7.59(t,J＝7.2Hz,2H),7.40(t,J＝7.5Hz,2H),7.35-7.28(m,2H),7.27(s,1H),7.09(s,1H),6.57(s,1H),5.65(d,J＝7.2Hz,1H),4.41(dd,J＝12.1,7.0Hz,4H),4.21(t,J＝7.0Hz,2H),3.42-3.32(m,1H),3.31-3.21(m,1H),2.35-2.18(m,3H),2.10-1.99(m,2H),1.92-1.81(m,1H),1.47(s,9H)；
(4)化合物4的合成
将化合物3(602mg，1.04mmol)溶于10mL二氯甲烷中，逐滴加入二乙胺(2.49g，33.98mmol)，室温搅拌3小时，减压旋蒸，除去溶剂，得到淡黄色固体状中间体，将Fmoc-L-苯丙氨酸(327mg，0.84mmol)溶于3mL超干N,N-二甲基甲酰胺中，冰浴下加入2-(7-氮杂苯并三氮唑)-N,N,N',N'-四甲基脲六氟磷酸酯(HATU)(386mg，1.02mmol)和N,N-二异丙基乙胺(DIPEA)(218mg，1.69mmol)，冰浴搅拌25分钟，将溶于3mL超干N,N-二甲基甲酰胺的淡黄色固体状中间体(300mg，0.84mmol)加入上述反应液，反应液于室温反应过夜，反应液用乙酸乙酯和饱和食盐水洗涤5次，收集有机相并用无水硫酸钠干燥，过滤除掉无水硫酸钠，滤液减压旋蒸浓缩，析出白色固体化合物4(362mg，0.50mmol)，产率：60％；
化合物4的结构确认：
HRMS C39H45N6O8[M+H]+理论分子量725.3298，实测分子量725.3300；
1H NMR(400MHz,(CD3)2SO)δ8.42(d,J＝7.3Hz,1H),7.97-7.77(m,3H),7.68(s,1H),7.66-7.56(m,3H),7.44-7.37(m,2H),7.36-7.31(m,2H),7.30-7.23(m,4H),7.22-7.15(m,2H),4.45-4.24(m,3H),4.23-3.97(m,4H),3.05(dd,J＝13.6,8.7Hz,3H),2.78(t,J＝12.5Hz,1H),2.18(t,J＝7.4Hz,2H),2.05-1.94(m,1H),1.94-1.76(m,3H),1.40(s,9H)；
(5)化合物5的合成
将化合物4(500mg，0.69mmol)溶于2mL二氯甲烷中，加入2mL三氟乙酸，室温搅拌30分钟，减压旋蒸除溶剂，得到橙黄色油状中间体，将中间体(358mg，0.54mmol)溶于4mL超干N,N-二甲基甲酰胺中，冰浴下加入HATU(240mg，0.63mmol)和DIPEA(134mg，1.04mmol)，冰浴搅拌30分钟，将溶于3mL超干N,N-二甲基甲酰胺的化合物1(276mg，0.57mmol)加入上述反应液，室温反应过夜，反应液用乙酸乙酯和饱和食盐水洗涤5次，收集有机相并用无水硫酸钠干燥，过滤除掉无水硫酸钠，滤液减压旋蒸除溶剂，剩余物通过快速纯化色谱仪纯化(二氯甲烷/甲醇/氨水，v/v/v＝15/1/0.1)，得到淡黄色固体状化合物5(408mg，0.36mmol)，产率：67％；
化合物5的结构确认：
HRMS C59H80N9O14[M+H]+理论分子量1138.5819，实测分子量1138.5824；
1H NMR(400MHz,CDCl3)δ7.90(s,1H),7.73(d,J＝7.4Hz,2H),7.50(d,J＝7.2Hz,2H),7.37(t,J＝7.3Hz,2H),7.30-7.21(m,11H),7.08(d,J＝12.1Hz,1H),6.97(s,1H),5.79(s,1H),5.29(s,1H),4.54-4.29(m,6H),4.27-4.09(m,3H),3.43-2.90(m,6H),2.30(s,4H),2.18-1.92(m,6H),1.91-1.75(m,1H),1.74-1.54(m,2H),1.46-1.37(m,27H),1.25(t,J＝7.1Hz,2H)；
(6)HBED-CC-NI-PSMA的合成
将化合物5(191mg，0.17mmol)溶于3mL二氯甲烷中，加入1mL二乙胺，室温搅拌3小时，减压旋蒸除溶剂，得到黄色油状中间体，HBED-CC(39mg，0.06mmol)溶于2mL超干N,N-二甲基甲酰胺中，冰浴下加入HATU(27.4mg，0.07mmol)和DIPEA(15.51mg，0.12mmol)，冰浴搅拌30分钟后，将溶于2mL超干N,N-二甲基甲酰胺的化合物5(61.9mg，0.07mmol)加入上述反应液，室温反应过夜，反应液用乙酸乙酯和饱和食盐水洗涤5次，收集有机相并用无水硫酸钠干燥，过滤除掉无水硫酸钠，滤液减压旋蒸除溶剂，利用快速纯化色谱仪纯化(二氯甲烷/甲醇/氨水，v/v/v＝9/1/0.1)，得到黄色油状物，再利用三氟乙酸脱保护得到HBED-CC-NI-PSMA粗产物，粗产物用高效液相色谱纯化，半制备色谱柱：Eclipse XDB-C18，5μm，9.4×250mm，分离条件：A相：0.1％TFA水，B相：0.1％TFA乙腈。梯度：0-12min，5％-55％B；12-13min，55％-100％B；13-16min，100％B；16-17min，100％-5％B；17-20min，5％B，流速：4mL/min，紫外：280nm，目标组分通过冷冻干燥，得到白色固体状化合物HBED-CC-NI-PSMA；
HBED-CC-NI-PSMA的结构确认：
HRMS C58H77N11O21[M+H]+理论分子量1262.5211，实测分子量1262.5220；
步骤2：含有硝基芳香杂环基团的PSMA靶向放射性配体HBED-CC-NI-PSMA的68Ga标记：
68Ga标记路线如下:
将步骤1得到的HBED-CC-NI-PSMA溶于二甲基亚砜配成1μg/μL的前体溶液，取4μL前体溶液于10mL西林瓶中，加入135μL 3M的醋酸钠溶液，用6mL的0.6M的高纯盐酸溶液淋洗锗镓发生器(iThemba)，得[68Ga]GaCl3盐酸溶液，取300μL，加入放射性配体醋酸钠混合溶液中，混合均匀后，在50℃下反应10分钟，冷却至室温，用带放射性检测器的高效液相色谱测定其放射化学纯度，得放射化学产率大于98％的[68Ga]Ga-HBED-CC-NI-PSMA。
如图1所示，为本发明实施例1中制备的[68Ga]Ga-HBED-CC-NI-PSMA的标记反应液的放射性HPLC图谱，图谱显示，[68Ga]Ga-HBED-CC-NI-PSMA的放射化学纯度大于98％；
实施例2：[68Ga]Ga-AAZTA-NI-PSMA的制备
步骤1：含有硝基芳香杂环基团的PSMA靶向放射性配体AAZTA-NI-PSMA的合成
合成路线如下：
具体包括以下步骤：
AAZTA-NI-PSMA的合成
将化合物5(191mg，0.17mmol)溶于3mL二氯甲烷中，加入1mL二乙胺，室温搅拌3小时，减压旋蒸除溶剂，得到黄色油状中间体，将AAZTA(41mg，0.06mmol)溶于2mL超干N,N-二甲基甲酰胺中，冰浴下加入HATU(27.4mg，0.07mmol)和DIPEA(15.51mg，0.12mmol)，冰浴搅拌30分钟，将溶于2mL超干N,N-二甲基甲酰胺的黄色油状中间体(61.9mg，0.07mmol)加入上述反应液，室温反应过夜，反应液用乙酸乙酯和饱和食盐水洗涤5次，收集有机相并用无水硫酸钠干燥，过滤，除掉无水硫酸钠，滤液减压旋蒸，除去溶剂，利用快速纯化色谱仪纯化(二氯甲烷/甲醇/氨水，v/v/v＝10/1/0.1)，得到黄色油状物，再通过三氟乙酸脱保护得到AAZTA-NI-PSMA粗产物，粗产物用高效液相色谱纯化，半制备色谱柱：Eclipse XDB-C18，5μm，9.4×250mm，分离条件：A相：0.1％TFA水，B相：0.1％TFA乙腈；梯度：0-16min，5％-41％B；16-16.5min，41％-100％B；16.5-20min，100％B；20-20.5min，100％-5％B；20.5-23min，5％B，流速：4mL/min，紫外：280nm，目标组分通过冷冻干燥得到白色固体状化合物AAZTA-NI-PSMA；
AAZTA-NI-PSMA的结构确认：经LC-MS测定，纯度大于98％；
步骤2：含有硝基芳香杂环基团的PSMA靶向放射性配体AAZTA-NI-PSMA的68Ga标记
68Ga标记路线如下:
将步骤1得到的AAZTA-NI-PSMA溶于二甲基亚砜配成1μg/μL的前体溶液，取10μL前体溶液于10mL西林瓶中，加入135μL 3M的醋酸钠溶液，用6mL 0.6M的高纯盐酸溶液淋洗锗镓发生器(iThemba)，得到[68Ga]GaCl3盐酸溶液，取300μL，加入放射性配体醋酸钠混合溶液中，混合均匀后，在50℃下反应10分钟，冷却至室温，用带放射性检测器的高效液相色谱测定其放射化学纯度，得放射化学产率大于98％的[68Ga]Ga-AAZTA-NI-PSMA。
如图2所示，为本发明实施例2中制备的[68Ga]Ga-AAZTA-NI-PSMA的标记反应液的放射性HPLC图谱，图谱显示，[68Ga]Ga-AAZTA-NI-PSMA的放射化学纯度大于98％；
实施例3：[68Ga]Ga-DOTA-NI-PSMA的制备
步骤1：含有硝基芳香杂环基团的PSMA靶向放射性配体DOTA-NI-PSMA的合成：
合成路线如下：
DOTA-NI-PSMA的合成
将化合物5(191mg，0.17mmol)溶于3mL二氯甲烷中，加入1mL二乙胺，室温搅拌3小时，减压旋蒸除溶剂，得到黄色油状中间体，将1,4,7,10-四氮杂环十二烷-1,4,7,10-四乙酸三叔丁酯(DOTA，34.34mg，0.06mmol)溶于2mL超干N,N-二甲基甲酰胺中，冰浴下加入HATU(29.66mg，0.08mmol)和DIPEA(15.51mg，0.12mmol)，冰浴搅拌30分钟，将溶于2mL超干N,N-二甲基甲酰胺的黄色油状中间体(50mg，0.05mmol)加入上述反应液，室温反应，过夜，反应液用乙酸乙酯和饱和食盐水洗涤5次，收集有机相并用无水硫酸钠干燥，过滤，除掉无水硫酸钠，滤液减压旋蒸，除去溶剂，利用快速纯化色谱仪纯化(二氯甲烷/甲醇/氨水，v/v/v＝10/1/0.1)，得到黄色油状物，再通过三氟乙酸脱保护得到DOTA-NI-PSMA粗产物，粗产物用高效液相色谱纯化，半制备色谱柱：Eclipse XDB-C18，5μm，9.4×250mm，分离条件：A相：0.1％TFA水，B相：0.1％TFA乙腈。梯度：0-15min，5％-100％B；15-17min，100％B；17-17.5min，100％-5％B；17.5-20min，5％B，流速：4mL/min，紫外：280nm，目标组分通过冷冻干燥得到白色固体状化合物DOTA-NI-PSMA；
DOTA-NI-PSMA的结构确认：
HRMS C48H73N13O19[M+H]+理论分子量1134.5061，实测分子量1134.5046；
步骤2：含有硝基芳香杂环基团的PSMA靶向放射性配体DOTA-NI-PSMA的68Ga标记
68Ga标记路线如下:
将步骤1得到的DOTA-NI-PSMA溶于二甲基亚砜配成1μg/μL的前体溶液，取17μL前体溶液于10mL西林瓶中，加入72μL 3M的醋酸钠溶液，用6mL 0.6M的高纯盐酸溶液淋洗锗镓发生器(iThemba)，得到[68Ga]GaCl3盐酸溶液，取300μL，加入放射性配体醋酸钠混合溶液中，混合均匀后，在95℃下反应15分钟，冷却至室温，用带放射性检测器的高效液相色谱测定其放射化学纯度，得放射化学产率大于98％的[68Ga]Ga-DOTA-NI-PSMA。
如图3所示，为本发明实施例3中制备的[68Ga]Ga-DOTA-NI-PSMA的标记反应液的放射性HPLC图谱，图谱显示，[68Ga]Ga-DOTA-NI-PSMA的放射化学纯度大于98％；
实施例4：[68Ga]Ga-HBED-CC-NI-PSMA-11的制备
步骤1：含有硝基芳香杂环基团的PSMA靶向放射性配体HBED-CC-NI-PSMA-11的合成
合成路线如下：
具体包括以下步骤：
(1)化合物6的合成
将CBz-6氨基己酸(356mg，1.34mmol)溶于7mL超干N,N-二甲基甲酰胺中，在冰浴条件下加入HATU(245mg,0.64mmol)和DIPEA(150mg,1.16mmol)，冰浴搅拌30分钟，随后将溶于5mL超干N,N-二甲基甲酰胺的化合物1(259mg,0.53mmol)加入上述反应液，室温反应，过夜，反应液用饱和食盐水和乙酸乙酯洗涤，收集有机相并用无水硫酸钠干燥，减压旋蒸，除去溶剂，剩余物通过硅胶柱色谱纯化(石油醚/乙酸乙酯，v/v＝1/3)，得到无色油状物，再通过氢气还原得到化合物6；
化合物6的结构确认：
HRMS C30H57N4O8[M+H]+理论分子量601.417，实测分子量601.4177；
1H NMR(400MHz,(CD3)2SO)δ7.83-7.64(m,1H),6.30(dd,J＝16.2,8.3Hz,2H),4.02(dd,J＝8.5,5.3Hz,1H),3.94(dd,J＝13.5,7.7Hz,1H),2.99(dd,J＝12.3,5.5Hz,4H),2.52-2.46(m,2H),2.34-2.09(m,3H),2.01(t,J＝7.5Hz,2H),1.86(ddd,J＝20.7,10.4,6.2Hz,1H),1.72-1.44(m,6H),1.41-1.36(m,27H),1.31-1.13(m,6H)；
(2)化合物7的合成
将化合物4(500mg，0.69mmol)溶于2mL二氯甲烷中，加入2mL三氟乙酸，室温搅拌30分钟，减压旋蒸，除去溶剂，得到橙黄色油状中间体，将橙黄色油状中间体(287mg，0.43mmol)溶于3mL超干N,N-二甲基甲酰胺中，冰浴下加入HATU(183mg，0.48mmol)和DIPEA(105mg，0.81mmol)，冰浴搅拌30分钟，将溶于3mL超干N,N-二甲基甲酰胺的化合物6(240mg，0.40mmol)加入上述反应液，室温反应过夜，反应液用乙酸乙酯和饱和食盐水洗涤5次，收集有机相并用无水硫酸钠干燥，过滤除掉无水硫酸钠，滤液减压旋蒸，除去溶剂，剩余物通过快速纯化色谱仪纯化(二氯甲烷/甲醇/氨水，v/v/v，10/1/0.1)，得到淡黄色固体状化合物7(305mg，0.24mmol)，产率：61％；
化合物7的结构确认：
HRMS C65H91N10O15[M+H]+理论分子量1251.6659，实测分子量1251.6666；
1H NMR(600MHz,CDCl3)δ7.85(s,1H),7.74(d,J＝7.6Hz,2H),7.51(d,J＝7.5Hz,2H),7.37(ddd,J＝7.6,5.5,2.0Hz,2H),7.31(s,1H),7.29-7.26(m,3H),7.26-7.24(m,1H),7.24-7.17(m,2H),7.08(s,1H),6.96(s,1H),5.86(d,J＝5.2Hz,1H),4.54-4.44(m,2H),4.44-4.38(m,3H),4.37-4.28(m,2H),4.23-4.10(m,2H),3.37-3.23(m,3H),3.22-3.11(m,4H),3.08-3.00(m,1H),2.36-2.26(m,4H),2.22(t,J＝6.3Hz,2H),2.13-1.91(m,6H),1.88-1.74(m,2H),1.70-1.63(m,1H),1.62-1.56(m,2H),1.55-1.48(m,3H),1.47-1.42(m,20H),1.40(s,10H),1.35-1.24(m,6H)；
(3)HBED-CC-NI-PSMA-11的合成
将化合物7(305mg，0.24mmol)溶于5mL二氯甲烷中，加入1mL二乙胺，室温搅拌3小时，减
压旋蒸，除去溶剂，得到黄色油状中间体，将HBED-CC(33mg，0.05mmol)溶于2mL超干N,N-二甲基甲酰胺中，冰浴下加入HATU(25mg，0.07mmol)和DIPEA(13mg，0.10mmol)，冰浴搅拌30分钟，将溶于2mL超干N,N-二甲基甲酰胺的黄色油状中间体(50mg，0.05mmol)加入上述反应液，室温反应过夜，反应液用乙酸乙酯和饱和食盐水洗涤5次，收集有机相并用无水硫酸钠干燥，过滤除掉无水硫酸钠，滤液减压旋蒸，除去溶剂，利用快速纯化色谱仪纯化(二氯甲烷/甲醇/氨水，v/v/v＝10/1/0.1)，得到黄色油状物，再利用三氟乙酸脱保护得到HBED-CC-PSMA-11粗产物，粗产物用高效液相色谱纯化，半制备色谱柱：Eclipse XDB-C18，5μm，9.4×250mm，分离条件：A相：0.1％TFA水，B相：0.1％TFA乙腈。梯度：0-15min，5％-65％B；15-16min，65％-100％B；16-19min，100％B；19-20min，100％-5％B；20-23min，5％B，流速：4mL/min，紫外：280nm，目标组分通过冷冻干燥得到白色固体状化合物HBED-CC-NI-PSMA-11；
化合物HBED-CC-NI-PSMA-11的结构确认：
HRMS C64H87N12O22[M+H]+理论分子量1375.6052，实测分子量1375.6068；
步骤2：含有硝基芳香杂环基团的PSMA靶向放射性配体HBED-CC-NI-PSMA-11的68Ga标记
68Ga标记路线如下：
将步骤1得到的HBED-CC-NI-PSMA-11溶于二甲基亚砜配成1μg/μL的前体溶液，取5μL前体溶液于10mL西林瓶中，加入135μL 3M的醋酸钠溶液，用6mL 0.6M的高纯盐酸溶液淋洗锗镓发生器(iThemba)，得到[68Ga]GaCl3盐酸溶液，取300μL，加入放射性配体醋酸钠混合溶液中，混合均匀后，在50℃下反应10分钟，冷却至室温，用带放射性检测器的高效液相色谱测定其放射化学纯度，得放射化学产率大于98％的[68Ga]Ga-HBED-CC-NI-PSMA-11。
如图4所示，为本发明实施例4中制备的[68Ga]Ga-HBED-CC-NI-PSMA-11的标记反应液放射性HPLC图谱，图谱显示，[68Ga]Ga-HBED-CC-NI-PSMA-11的放射化学纯度大于98％；
实施例5：[68Ga]Ga-AAZTA-NI-PSMA-11的制备
步骤1：含有硝基芳香杂环基团的PSMA靶向放射性配体AAZTA-NI-PSMA-11的合成
合成路线如下：
将化合物7(305mg，0.24mmol)溶于5mL二氯甲烷中，加入1mL二乙胺，室温搅拌3小时，减压旋蒸，除去溶剂，得到黄色油状中间体，将AAZTA(33.57mg，0.05mmol)溶于2mL超干N,N-二甲基甲酰胺中，冰浴下加入HATU(25mg，0.07mmol)和DIPEA(13mg，0.10mmol)，冰浴搅拌30分钟，将溶于2mL超干N,N-二甲基甲酰胺的黄色油状中间体(50mg，0.05mmol)加入上述反应液，室温反应过夜，反应液用乙酸乙酯和饱和食盐水洗涤5次，收集有机相并用无水硫酸钠干燥，过滤，除掉无水硫酸钠，滤液减压旋蒸，除去溶剂，利用快速纯化色谱仪纯化(二氯甲烷/甲醇/氨水，v/v/v＝10/1/0.1)，得到黄色油状物，再利用三氟乙酸脱保护得到AAZTA-NI-PSMA-11粗产物，粗产物
用高效液相色谱纯化，半制备色谱柱：Eclipse XDB-C18，5μm，9.4×250mm，分离条件：A相：0.1％TFA水，B相：0.1％TFA乙腈。梯度：0-15min，5％-100％B；15-17min，100％B；17-17.5min，100％-5％B；17.5-20min，5％B，流速：4mL/min，紫外：280nm，目标组分通过冷冻干燥，得到白色固体状化合物AAZTA-NI-PSMA-11；
化合物AAZTA-NI-PSMA-11的结构确认：
HRMS C56H84N13O22[M+H]+理论分子量1290.5848，实测分子量1290.5859；
步骤2：含有硝基芳香杂环基团的PSMA靶向放射性配体AAZTA-NI-PSMA-11的68Ga标记：
68Ga标记路线如下:
将步骤1得到的AAZTA-NI-PSMA-11溶于二甲基亚砜配成1μg/μL的前体溶液，取10μL前体溶液于10mL西林瓶中，加入135μL 3M的醋酸钠溶液，用6mL 0.6M的高纯盐酸溶液淋洗锗镓发生器(iThemba)，得到[68Ga]GaCl3盐酸溶液，取300μL加入放射性配体醋酸钠混合溶液中，混合均匀后，在50℃下反应10分钟，冷却至室温，用带放射性检测器的高效液相色谱测定其放射化学纯度，得放射化学产率大于98％的[68Ga]Ga-AAZTA-NI-PSMA-11。
如图5所示，为本发明实施例5中制备的[68Ga]Ga-AAZTA-NI-PSMA-11的标记反应液的放射性HPLC图谱，图谱显示，[68Ga]Ga-AAZTA-NI-PSMA-11的放射化学纯度大于98％；
实施例6：[68Ga]Ga-DOTA-NI-PSMA-11的制备
步骤1：含有硝基芳香杂环基团的PSMA靶向放射性配体DOTA-NI-PSMA-11的合成
合成路线如下：
将化合物7(305mg，0.24mmol)溶于5mL二氯甲烷中，加入1mL二乙胺，室温搅拌3小时，减压旋蒸，除去溶剂，得到黄色油状中间体，将DOTA(29mg，0.05mmol)溶于2mL超干N,N-二甲基甲酰胺中，冰浴下加入HATU(25mg，0.07mmol)和DIPEA(13mg，0.10mmol)，冰浴搅拌30分钟，将溶于2mL超干N,N-二甲基甲酰胺的黄色油状中间体(50mg，0.05mmol)加入上述反应液，室温反应过夜，反应液用乙酸乙酯和饱和食盐水洗涤5次，收集有机相并用无水硫酸钠干燥，过滤，除掉无水硫酸钠，滤液减压旋蒸，除去溶剂，利用快速纯化色谱仪纯化(二氯甲烷/甲醇/氨水，v/v/v＝10/1/0.1)，得到黄色油状物，再用三氟乙酸脱保护得到DOTA-NI-PSMA-11粗产物，粗产物用高效液相色谱纯化，半制备色谱柱：Eclipse XDB-C18，5μm，9.4×250mm，分离条件：A相：0.1％TFA水，B相：0.1％TFA乙腈，梯度：0-15min，5％-100％B；15-17min，100％B；17-17.5min，100％-5％B；17.5-20min，5％B，流速：4mL/min，紫外：280nm，目标组分通过冷冻干燥，得到白色固体状化合物DOTA-NI-PSMA-11；
化合物DOTA-NI-PSMA-11的结构确认：
HRMS C54H83N14O20[M+H]+理论分子量1247.5902，实测分子量1247.5896；
步骤2：含有硝基芳香杂环基团的PSMA靶向放射性配体DOTA-NI-PSMA-11的68Ga标记：
68Ga标记路线如下:
将步骤1得到的DOTA-NI-PSMA-11溶于二甲基亚砜配成1μg/μL的前体溶液，取25μL前体溶液于10mL西林瓶中，加入72μL 3M的醋酸钠溶液，用6mL 0.6M的高纯盐酸溶液淋洗锗镓发生器(iThemba)，得到[68Ga]GaCl3盐酸溶液，取300μL，加入放射性配体醋酸钠混合溶液中，混合均匀后，在95℃下反应15分钟，冷却至室温，用带放射性检测器的高效液相色谱测定其放射化学纯度，得放射化学产率大于98％的[68Ga]Ga-DOTA-NI-PSMA-11。
如图6所示，为本发明实施例6中制备的[68Ga]Ga-DOTA-NI-PSMA-11的标记反应液的放射性HPLC图谱，图谱显示，[68Ga]Ga-DOTA-NI-PSMA-11的放射化学纯度大于98％；
实施例7：[68Ga]Ga-AAZTA-NI-PSMA-093的制备
步骤1：含有硝基芳香杂环基团的PSMA靶向放射性配体AAZTA-NI-PSMA-093的合成
合成路线如下：
具体包括以下步骤：
(1)化合物8的合成
将N-苄氧羰基-L-苯丙氨酸(N-Cbz-L-Phe，1.42g，4.73mmol)溶于11mLN,N-二甲基甲酰胺中，于0摄氏度下加入1-羟基苯并三唑(HOBt，872mg，6.45mmol)，N,N-二异丙基乙胺(DIPEA，2.20mL，1.72g，12.9mmol)，1-乙基-(3-二甲基氨基丙基)碳酰二亚胺盐酸盐(EDCl，1.24g，6.45mmol)；将化合物1(2.10g，4.30mmol)溶解于15mLN,N-二甲基甲酰胺中，滴加入上述溶液，反应液室温下搅拌反应27小时，加入饱和氯化钠溶液和乙酸乙酯萃取，有机相使用饱和氯化钠溶液洗涤三次，加入无水硫酸钠干燥，过滤，滤液浓缩后，使用硅胶柱色谱纯化(二氯甲烷/甲醇/氨水＝95/5/0.5，v/v/v)，得到白色固体化合物(1.29g，1.67mmol，产率：38.9％)，将白色固体化合物(1.29g，1.67mmol)溶于20mL无水乙醇中，加入10％Pd/C(88.1mg)，混合物于氢气气氛中室温下搅拌反应27小时，所得反应液使用硅藻土抽滤，滤液减压旋蒸，除去溶剂，得到棕色油状化合物8(981mg，1.55mmol)，产率：92.5％；
化合物8的结构确认：
HRMS C33H55N4O8[M+H]+理论分子量635.4014,实测分子量635.4011；
1HNMR(600MHz,CDCl3)δ:7.33-7.18(m,5H),5.40(dd,2H,J＝10.6,8.1Hz),4.30(dtd,2H,J 28.9,8.0,4.9Hz),3.59(dd,1H,J＝9.3,4.2Hz),3.30-3.16(m,3H),2.67(dd,1H,J＝13.7,9.3Hz),2.37-2.23(m,2H),2.09-2.01(m,1H),1.88-1.70(m,3H),1.65-1.56(m,1H),1.51-1.46(m,2H),1.45-1.41(m,27H),1.37-1.28(m,2H)；
(2)化合物10的合成
将化合物8(959mg，1.51mmol)溶于15mLN,N-二甲基甲酰胺中，于0摄氏度下加入1-羟基苯并三唑(HOBt，237mg，1.75mmol)，N,N-二异丙基乙胺(DIPEA，0.60mL，469mg，3.63mmol)，1-乙基-(3-二甲基氨基丙基)碳酰二亚胺盐酸盐(EDCl，337mg，1.75mmol)，将化合物9(569mg，1.17mmol)溶解于15mL N,N-二甲基甲酰胺中，滴加入上述溶液，反应液室温下搅拌反应13.5小时，加入饱和氯化钠溶液和乙酸乙酯，萃取，有机相使用饱和氯化钠溶液洗涤三次，加入无水硫酸钠，干燥，过滤，滤液浓缩后，使用硅胶柱色谱纯化(二氯甲烷/甲醇/氨水＝95/5/0.5，v/v/v)，得到白色固体化合物10(725mg，0.657mmol)，产率：56.2％；
化合物10的结构确认：
HRMS理论分子量C58H83N6O15[M+H]+1103.5910,实测分子量1103.5927；
1HNMR(600MHz,CDCl3)δ:8.09(br s,1H),7.56(br s,1H),7.39-7.28(m,5H),7.28-7.17(m,5H),6.87(d,2H,J＝7.7Hz),6.59(d,2H,J＝7.8Hz),5.80(br s,1H),5.06(d,2H,J＝12.1Hz),4.92(d,1H,J＝12.0Hz),4.81(br s,1H),4.76-4.59(m,1H),4.52(br s,1H),4.41(br s,2H),4.05(d,1H,J＝14.3Hz),3.86(dd,1H,J＝17.4,3.3Hz),3.44(br s,2H),3.27-3.17(m,2H),3.15-2.96(m,2H),2.88(br s,1H),2.44-2.28(m,2H),2.12-2.02(m,1H),1.87-1.79(m,1H),1.58(d,2H,J＝6.3Hz),1.53-1.28(m,36H),1.28-1.19(m,2H),1.05
(brs,1H)；
(6)化合物11的合成
将化合物2(432mg，1.60mmol)溶于4mL三氟乙酸中，室温搅拌30分钟，通过减压旋蒸，除去溶剂，得到白色固体状中间体，将白色固体状中间体(812mg，3.00mmol)溶于6mL二氯甲烷中，加入2.5mL三氟乙酸，混合物于室温下搅拌反应40min，反应液减压旋蒸，除去溶剂，得到黄色油状化合物，备用，将N-叔丁氧羰基-L-谷氨酸-5-甲酯(530mg，2.03mmol)溶于10mL N,N-二甲基甲酰胺中，于0℃下加入1-羟基苯并三唑(HOBt，410mg，3.03mmol)，N,N-二异丙基乙胺(DIPEA，0.90mL，704mg，5.45mmol)，1-乙基-(3-二甲基氨基丙基)碳酰二亚胺盐酸盐(EDCl，572mg，2.99mmol)，将上述黄色油状化合物溶解于10mL N,N-二甲基甲酰胺中，滴加入上述溶液，反应液室温下搅拌反应26h，加入饱和氯化钠溶液和乙酸乙酯萃取，有机相使用饱和氯化钠溶液洗涤三次，加入无水硫酸钠，干燥，过滤，滤液浓缩后，使用硅胶柱色谱纯化(DCM/MeOH/NH4OH＝90/9/0.9，v/v/v)，得到黄色油状化合物11(434mg，1.05mmol)，产率：35.0％；
化合物11的结构确认：
HRMS C17H28N5O7[M+H]+理论分子量414.1983，实测分子量414.1978；
1HNMR(400MHz,CDCl3)δ:7.32(s,1H),7.14(s,1H),6.71(br s,1H),5.36(d,1H,J＝7.1Hz),4.44(t,2H,J＝6.9Hz),4.11(q,1H,J＝7.1Hz),3.69(s,3H),3.34(dd,2H,J＝12.5,6.2Hz),2.58-2.36(m,2H),2.20-2.02(m,3H),2.01-1.86(m,1H),1.43(s,9H)；
(7)化合物12的合成
将化合物12(152mg，0.367mmol)溶于6mL二氯甲烷中，加入2mL三氟乙酸，混合物于室温下搅拌反应1h，反应液减压旋蒸，除去溶剂，得到黄色油状化合物，备用，将AAZTA(149mg，0.223mmol)溶于7mL N,N-二甲基甲酰胺中，于0℃下加入O-(7-氮杂苯并三唑-1-基)-N,N,N’,N’-四甲基脲六氟磷酸酯(HATU，161mg，0.423mmol)和N,N-二异丙基乙胺(DIPEA，0.05mL，37.1mg，0.287mmol)，混合物搅拌反应30min，将上述黄色油状化合物溶解于5mL N,N-二甲基甲酰胺中，滴加入上述溶液，反应液室温下搅拌反应27h，加入饱和氯化钠溶液和乙酸乙酯，萃取，有机相使用饱和氯化钠溶液洗涤三次，加入无水硫酸钠，干燥，过滤，滤液浓缩后，使用硅胶柱色谱纯化(DCM/MeOH/NH4OH＝100/5/0.5，v/v/v)，得到黄色油状化合物12(71.9mg，0.0743mmol)，产率：33.8％；
化合物12的结构确认：
HRMS C46H79N8O14[M+H]+理论分子量967.5710，实测分子量967.5715；
1HNMR(600MHz,CDCl3)δ:7.43(s,1H),7.11(s,1H),6.88-6.78(m,1H),6.74-6.66(m,1H),4.50-4.30(m,3H),3.68(s,3H),3.66-3.55(m,2H),3.54(s,2H),3.47-3.36(m,3H),3.34-3.25(m,3H),3.08-2.98(m,2H),2.90-2.81(m,1H),2.73-2.66(m,1H),2.52-2.39(m,2H),2.37-2.25(m,2H),2.11-1.99(m,4H),1.72(s,8H),1.50-1.41(m,36H)；
(8)化合物13的合成
将化合物12(56.4mg，58.3μmol)溶于3mL四氢呋喃中，滴加浓度为1M的氢氧化钠溶液(1.0mL，1.0mmol)，室温搅拌反应8h，所得反应液，滴加浓度为1M的盐酸，调pH为6，所得溶液加入饱和食盐水和乙酸乙酯，萃取，水相使用乙酸乙酯洗涤3次，合并有机相，无水硫酸钠干燥，过滤，滤液减压旋蒸，除去溶剂，浓缩液使用硅胶柱色谱纯化(DCM/MeOH/NH3·H2O＝90/9/0.9，v/v/v)，得到白色固体化合物13(18.6mg，19.5μmol)，产率：32.5％；
化合物13的结构确认：
HRMS C45H77N8O14[M+H]+理论分子量953.5553，实测分子量953.5543；
(9)化合物AAZTA-NI-PSMA-093的合成
将化合物13(18.6mg，19.5μmol)溶于3mL N,N-二甲基甲酰胺中，于0℃下加入O-(7-氮杂苯并
三唑-1-基)-N,N,N′,N′-四甲基脲六氟磷酸酯(HATU，10.2mg，26.8μmol)和N,N-二异丙基乙胺(DIPEA，8.30mg，64.2μmol)，混合物搅拌反应30min，将化合物10溶解于2mL N,N-二甲基甲酰胺中，滴加入上述溶液，反应液室温下搅拌反应24h，加入饱和氯化钠溶液和乙酸乙酯，萃取，有机相使用饱和氯化钠溶液洗涤三次，加入无水硫酸钠，干燥，过滤，滤液浓缩后，使用硅胶柱色谱纯化(DCM/MeOH/NH4OH＝100/5/0.5，v/v/v)，得到黄色油状化合物(11.5mg，6.04μmol，产率：30.2％)。将黄色油状化合物(11.5mg，6.04μmol)溶于2mL二氯甲烷中，加入2mL三氟乙酸，混合物于室温下搅拌反应3h，反应液减压旋蒸，除去溶剂，所得黄色固体溶于1.0mL二甲基亚砜中，该溶液使用半制备HPLC进行纯化，得到白色固体化合物AAZTA-NI-PSMA-093(2.50mg，4.54μmol)，产率：75.2％；
化合物AAZTA-NI-PSMA-093的结构确认：
HRMS C63H87N14O26[M+H]+理论分子量1511.6536，实测分子量1511.6548；
步骤2：含有硝基芳香杂环基团的PSMA靶向放射性配体AAZTA-NI-PSMA-093的68Ga标记：
68Ga标记路线如下:
将含20nmol的放射性配体AAZTA-NI-PSMA-093的二甲基亚砜溶液加入到150μL的3M的醋酸钠缓冲溶液中，用高纯盐酸溶液淋洗锗镓发生器(iThemba laboratories，740MBq，20mCi)，将所得的300μL[68Ga]GaCl3盐酸溶液加入放射性配体的醋酸钠缓冲溶液中，混合均匀，加水稀释反应液总体积为500μL，50℃反应10分钟，冷却至室温，用带放射性检测器的高效液相色谱(radio-HPLC)测定其标记率，得到放射化学纯度大于95％的[68Ga]Ga-AAZTA-NI-PSMA-093。
如图所示，为本发明实施例7中制备的[68Ga]Ga-AAZTA-NI-PSMA-093的标记反应液radio-HPLC图谱，图谱显示，[68Ga]Ga-AAZTA-NI-PSMA-093的放射化学纯度大于98％。
实施例8：[68Ga]Ga-NI-HBED-CC-PSMA-11的制备
步骤1：含有硝基芳香杂环基团的PSMA靶向放射性配体NI-HBED-CC-PSMA-11的合成：
合成路线如下：
具体包括以下步骤：
(1)化合物14的合成
将HBED-CC(200mg，0.310mmol)溶于10mL无水N,N-二甲基甲酰胺中，冰浴条件下向溶液中依次加入加入2-(7-氮杂苯并三氮唑)-N,N,N,N’-四甲基脲六氟磷酸酯(HATU，141mg，0.372mmol)，N,N’-二异丙基乙胺(DIPEA，80.0mg，0.620mmol)，将化合物2溶于2mL三氟乙酸，搅拌1h后减压蒸馏得到白色中间体，将白色固体状中间体(52.8mg，0.310mmol)溶于5mL无水DMF中滴加至上述溶液，室温搅拌4h后，向溶液中加入30mL饱和食盐水，乙酸乙酯萃取，去离子水(30mL×2)清洗有机相，减压蒸馏浓缩，利用硅胶色谱纯化(二氯甲烷/甲醇/氨水，v/v/v＝90/10/1)过，得到无色物体化合物14(68.7mg，0.0863mmol)，产率：27.8％；
化合物14的结构确认：
HRMS C50H76N6O13[M+H]+理论分子量969.5543，实测分子量969.5542；
1H NMR(400MHzCDOD)δ7.71(d,1H,J＝2.1Hz),7.39-7.28(m,1H),7.23-7.09(m,3H),7.06-6.93(m,1H),6.89(d,1H,J＝8.4Hz),6.70(d,1H,J＝8.4Hz),6.47(s,1H),5.77(d,1H,J＝4.5Hz),5.16-4.85(m,1H),4.74(dd,1H,J＝14.1,5.9Hz),4.56-4.19(m,3H),3.94-3.74(m,1H),3.39(d,2H,J＝16.3Hz),3.26-2.82(m,4H),2.34(ddd,2H,J＝30.4,18.4,13.8Hz),2.08(tdd,1H,J＝14.7,10.1,4.6Hz),1.84(ddd,1H,J＝19.8,12.3,7.9Hz),1.72-1.00(m,36H)；
(2)：NI-HBED-CC-PSMA-11的合成
将化合物14(20.1mg，25.1μmol)溶于5mL无水DMF，冰浴条件下依次加入2-(7-氮杂苯并三氮唑)-N,N,N,N’-四甲基脲六氟磷酸酯(HATU，14.3mg，30.1μmol)，N,N’-二异丙基乙胺(DIPEA，6.49mg，50.2μmol)，加入化合物6(15.1mg，25.0μmol)，室温搅拌过夜，向溶液中加入10mL饱和食盐水，乙酸乙酯萃取，去离子水(20mL×2)清洗有机相，减压蒸馏浓缩，使用硅胶色谱纯化(二氯甲烷/甲醇/氨水，v/v/v＝90/10/1)，得到无色固体化合物(19.0mg，13.8μmol)产率：55.0％；将无色固体化合物溶于2mL三氟乙酸，室温搅拌1h后，加入无水二氯甲烷稀释反应液，减压蒸馏，除去有机溶剂，利用Semi pre-HPLC纯化(A：0.1％TFA水溶液，B：0.1％TFA乙腈溶液，0-20min B 5％-100％，UV＝280nm，流速4mL/min)得到白色固体化合物25(3.5mg，3.18μmol)，产率：54.8％；
NI-HBED-CC-PSMA-11的结构确认：
HRMS C50H71N10O18[M+H]+理论分子量1099.4942，实测分子量1099.4940；
步骤2：含有硝基芳香杂环基团的PSMA靶向放射性配体NI-HBED-CC-PSMA-11的68Ga标记
68Ga标记路线如下:
将15μg的步骤1制备的放射性配体NI-HBED-CC-PSMA-11溶于135μL的3N的醋酸钠缓冲液，用6mL高纯0.6N盐酸溶液淋洗锗镓发生器(iThemba Laboratories，740MBq，20mCi)，将300μL所得[68Ga]GaCl3的盐酸溶液加入前体的醋酸钠溶液中，均匀混合，50℃反应10min，冷却至常温，用带放射性检测器的高效液相色谱(radio-HPLC)测定其标记率，得放射化学产率>98％的[68Ga]Ga-NI-HBED-CC-PSMA-11；
如图8所示，为本发明实施例8中制备的[68Ga]Ga-NI-HBED-CC-PSMA-11的标记反应液放射性HPLC图谱，图谱显示，[68Ga]Ga-NI-HBED-CC-PSMA-11的放射化学纯度大于98％。
实施例9：[68Ga]Ga-NI-DOTAGA2-PSMA-11的制备
步骤1：含有硝基芳香杂环基团的PSMA靶向放射性配体NI-DOTAGA2-PSMA-11的合成：
合成路线如下：
具体包括以下步骤：
(1)化合物15的合成
将DOTAGA2(200mg，0.259mmol)溶于10mL无水N,N-二甲基甲酰胺中，冰浴条件下向溶液中依次加入2-(7-氮杂苯并三氮唑)-N,N,N,N’-四甲基脲六氟磷酸酯(HATU，141mg，0.372mmol)，N,N’-二异丙基乙胺(DIPEA，66.8mg，0.518mmol)，将化合物2溶于2mL三氟乙酸，搅拌1h后，减压蒸馏，得到白色固体状中间体，将白色固体状中间体(44.1mg，0.259mmol)溶于5mL无水DMF中，滴加至上述溶液，室温搅拌4h后，向溶液中加入30mL饱和食盐水，乙酸乙酯萃取，去离子水(30mL×2)清洗有机相，减压蒸馏浓缩，利用硅胶色谱纯化(二氯甲烷/甲醇/氨水，v/v/v＝90/10/1)过，得到无色物体化合物15(86.5mg，0.0935mmol)，产率：36.1％；
化合物15的结构确认：
HRMS C44H77N8O13[M+H]+理论分子量925.5605,实测分子量925.5600；
(6)NI-DOTAGA2-PSMA-11的合成
将化合物15(25.6mg，27.6μmol)溶于5mL无水DMF，冰浴条件下依次加入2-(7-氮杂苯并三氮唑)-N,N,N,N’-四甲基脲六氟磷酸酯(HATU，14.3mg，30.1μmol)，N,N’-二异丙基乙胺(DIPEA，6.49mg，50.2μmol)，加入化合物15(15.1mg，25.0μmol)，室温搅拌过夜，向溶液中加入10mL饱和食盐水，乙酸乙酯萃取，去离子水(20mL×2)清洗有机相，减压蒸馏浓缩，使用硅胶色谱纯化(二氯甲烷/甲醇/氨水，v/v/v＝90/10/1)，得到无色固体化合物；将无色固体化合物溶于2mL三氟乙酸，室温搅拌1h后，加入无水二氯甲烷，稀释反应液，减压蒸馏，除去有机溶剂，利用Semi pre-HPLC纯化(A：0.1％TFA水溶液，B：0.1％TFA乙腈溶液，0-20min B 5％-100％，UV＝280nm，流速4mL/min)，得到白色固体化合物NI-DOTAGA2-PSMA-11(4.8mg，3.18μmol)，产率：54.8％；
NI-DOTAGA2-PSMA-11的结构确认：
HRMS C46H75N12O20[M+H]+理论分子量1115.5215,实测分子量1115.5210；
步骤2：含有硝基芳香杂环基团的PSMA靶向放射性配体NI-DOTAGA2-PSMA-11的68Ga标记：
68Ga标记路线如下：
将15μg的步骤1制备的放射性配体NI-DOTAGA2-PSMA-11溶于135μL的3N的醋酸钠缓冲液，用6mL高纯0.6N盐酸溶液淋洗锗镓发生器(iThemba Laboratories，740MBq，20mCi)，将300μL所得[68Ga]GaCl3的盐酸溶液加入前体的醋酸钠溶液中，均匀混合，50℃反应10min，冷却至常温，用带放射性检测器的高效液相色谱(radio-HPLC)测定其标记率，得放射化学产率>98％的[68Ga]Ga-NI-DOTAGA2-PSMA-11；
如图9所示，为本发明实施例9中制备的[68Ga]Ga-NI-HBED-CC-PSMA-11的标记反应液放射性HPLC图谱，图谱显示，[68Ga]Ga-NI-HBED-CC-PSMA-11的放射化学纯度大于98％。
实施例10：[68Ga]Ga-NI-HBED-CC-PSMA-093的制备
步骤1：含有硝基芳香杂环基团的PSMA靶向放射性配体NI-HBED-CC-PSMA-093的合成：
合成步骤如下:
将化合物14(20.1mg，25.1μmol)溶于5mL无水N,N-二甲基甲酰胺，冰浴条件下依次加入2-(7-氮杂苯并三氮唑)-N,N,N,N’-四甲基脲六氟磷酸酯(HATU，14.3mg，30.1μmol)，N,N’-二异丙基乙胺(DIPEA，6.49mg，50.2μmol)，加入化合物10(29.2mg，30.1μmol)，室温搅拌过夜，向溶液中加入10mL饱和食盐水，乙酸乙酯萃取，去离子水(20mL×2)清洗有机相，减压蒸馏浓缩，利用硅胶色谱纯化(二氯甲烷/甲醇/氨水，v/v/v，90/10/1)，得到无色固体化合物(16.8mg，9.61μmol)，产率：38.3％，将无色固体化合物(11.3mg，6.47μmol)溶于2mL三氟乙酸，室温搅拌1h后，加入无水二氯甲烷，稀释反应液，减压蒸馏，除去有机溶剂，利用Semi pre-HPLC纯化(A：0.1％TFA水溶液，B：0.1％TFA乙腈溶液，0-20min B 5％-100％，UV＝280nm，流速4mL/min)得到白色固体化合物NI-HBED-CC-PSMA-093(4.40mg，3.31μmol)，产率：51.1％；
NI-HBED-CC-PSMA-093的结构确认：
HRMS C66H83N12O23[M+H]+理论分子量1411.5688，实测分子量1411.5703；
步骤2：含有硝基芳香杂环基团的PSMA靶向放射性配体NI-HBED-CC-PSMA-093的68Ga标记：
68Ga标记路线如下：
将15μg的步骤1制备的放射性配体NI-HBED-CC-PSMA-093溶于135μL的3N的醋酸钠缓冲液，用6mL高纯0.6N盐酸溶液淋洗锗镓发生器(iThemba Laboratories，740MBq，20mCi)，将300μL所得[68Ga]GaCl3的盐酸溶液加入前体的醋酸钠溶液中，均匀混合，50℃反应10min，冷却至常温，用带
放射性检测器的高效液相色谱(radio-HPLC)测定其标记率，得放射化学产率>98％的[68Ga]Ga-NI-HBED-CC-PSMA-093；
如图10所示，为本发明实施例10中制备的[68Ga]Ga-NI-HBED-CC-PSMA-093的标记反应液的放射性HPLC图谱，图谱显示，[68Ga]Ga-NI-HBED-CC-PSMA-093的放射化学纯度大于98％。
实施例11：[68Ga]Ga-NI-DOTAGA2-PSMA-093的制备
步骤1：含有硝基芳香杂环基团的PSMA靶向放射性配体NI-DOTAGA2-PSMA-093的合成：
合成方案如下：
将化合物15(23.2mg，25.1μmol)溶于5mL无水N,N-二甲基甲酰胺，冰浴条件下依次加入2-(7-氮杂苯并三氮唑)-N,N,N,N’-四甲基脲六氟磷酸酯(HATU，14.3mg，30.1μmol)，N,N’-二异丙基乙胺(DIPEA，6.49mg，50.2μmol)，加入化合物10(29.2mg，30.1μmol)，室温搅拌过夜，向溶液中加入10mL饱和食盐水，乙酸乙酯萃取，去离子水(20mL×2)清洗有机相，减压蒸馏浓缩，利用硅胶色谱纯化(二氯甲烷/甲醇/氨水，v/v/v，90/10/1)，得到无色固体化合物(18.0mg，9.61μmol)，产率：38.3％，将无色固体化合物(11.3mg，6.01μmol，1eq.)溶于2mL三氟乙酸，室温搅拌1h后，加入无水二氯甲烷，稀释反应液，减压蒸馏，除去有机溶剂，利用Semi pre-HPLC纯化(A：0.1％TFA水溶液，B：0.1％TFA乙腈溶液，0-20min B 5％-100％，UV＝280nm，流速4mL/min)，得到白色固体化合物NI-DOTAGA2-PSMA-093(3.98mg，2.79μmol)，产率：46.4％；
NI-DOTAGA2-PSMA-093的结构确认:
HRMS C62H87N14O25[M+H]+理论分子量1427.5961，实测分子量1427.5956；
步骤2：含有硝基芳香杂环基团的PSMA靶向放射性配体NI-DOTAGA2-PSMA-093的68Ga标记：
68Ga标记路线如下：
将15μg的步骤1制备的放射性配体NI-DOTAGA2-PSMA-093溶于135μL的3N的醋酸钠缓冲液，用6mL高纯0.6N盐酸溶液淋洗锗镓发生器(iThemba Laboratories，740MBq，20mCi)，将300μL所得[68Ga]GaCl3的盐酸溶液加入前体的醋酸钠溶液中，均匀混合，50℃反应10min，冷却至常温，用带放射性检测器的高效液相色谱(radio-HPLC)测定其标记率，得放射化学产率>98％的[68Ga]Ga-NI-DOTAGA2-PSMA-093；
如图11所示，为本发明实施例11中制备的[68Ga]Ga-NI-HBED-CC-PSMA-093的标记反应液的放射性HPLC图谱，图谱显示，[68Ga]Ga-NI-HBED-CC-PSMA-093的放射化学纯度大于98％。
应用实施例1
[68Ga]Ga-AAZTA-NI-PSMA、[68Ga]Ga-AAZTA-NI-PSMA-11体外22RV1-FOLH1-oe细胞摄取：
将22RV1-FOLH1-oe细胞配制成1×105个/mL的细胞悬液，分别取500μL接种至6个12孔板中，各向组孔板中分别加入37KBq的[68Ga]Ga-AAZTA-NI-PSMA、[68Ga]Ga-AAZTA-NI-PSMA-11和[68Ga]Ga-HBED-CC-PSMA-11溶液，在37℃下，在各组孵育的第15、30、60、90和120分钟，使用PBS溶液终止其摄取，使用1M NaOH裂解细胞，使用滤纸吸取细胞裂解液塞入塑料试管中测定放射性计数；使用过量未标记的PSMA-11在60分钟时，阻断细胞摄取，孵育结束后，使用PBS溶液终止其摄取，使用1MNaOH裂解细胞，使用滤纸吸取细胞裂解液塞入塑料试管中测定放射性计数。
如图12所示为本发明应用实施例1中，体外22RV1-FOLH1-oe细胞摄取[68Ga]Ga-AAZTA-NI-PSMA、[68Ga]Ga-AAZTA-NI-PSMA-11和[68Ga]Ga-HBED-CC-PSMA-11的摄取量-时间曲线图(n＝3)；
如图13所示为本发明应用实施例1中，体外22RV1-FOLH1-oe细胞摄取实验分析[68Ga]Ga-AAZTA-NI-PSMA、[68Ga]Ga-AAZTA-NI-PSMA-11和[68Ga]Ga-HBED-CC-PSMA-11与前列腺特异型膜抗原受体的特异性结合图(n＝3)。
由体外细胞摄取实验结果可知，22RV1-FOLH1-oe细胞与[68Ga]Ga-AAZTA-NI-PSMA、[68Ga]Ga-AAZTA-NI-PSMA-11和[68Ga]Ga-HBED-CC-PSMA-11，随着孵育时间的延长，摄取先增加后降低，其中[68Ga]Ga-HBED-CC-PSMA-11在所有时间点的细胞摄取量均显著高于其它放射性金属配合物。在过量非放射性标记的PSMA-11存在下，放射性金属配合物的摄取显著降低，表明22RV1-FOLH1-oe细胞对配合物的摄取均为特异性摄取，PSMA与本发明的放射性金属配合物结合为特异性结合。
应用实施例2:
[68Ga]Ga-AAZTA-NI-PSMA、[68Ga]Ga-DOTA-NI-PSMA和[68Ga]Ga-HBED-CC-NI-PSMA体外22RV1-FOLH1-oe细胞摄取：
将22RV1-FOLH1-oe细胞配制成1.5×105个/mL的细胞悬液，分别取500μL接种至6个12孔板中，各向组孔板中分别加入37KBq的[68Ga]Ga-AAZTA-NI-PSMA、[68Ga]Ga-DOTA-NI-PSMA、[68Ga]Ga-HBED-CC-NI-PSMA和[68Ga]Ga-HBED-CC-PSMA-11溶液，在37℃下，在各组孵育的第15、30、60、90和120分钟，使用PBS溶液终止其摄取，使用1M NaOH裂解细胞，使用滤纸吸取细胞裂解液塞入塑料
试管中测定放射性计数；使用过量未标记的PSMA-11在60分钟时，阻断细胞摄取，孵育结束后，使用PBS溶液终止其摄取，使用1M NaOH裂解细胞，使用滤纸吸取细胞裂解液塞入塑料试管中测定放射性计数。
如图14所示为本发明应用实施例2中，体外22RV1-FOLH1-oe细胞摄取[68Ga]Ga-AAZTA-NI-PSMA、[68Ga]Ga-DOTA-NI-PSMA、[68Ga]Ga-HBED-CC-NI-PSMA和[68Ga]Ga-HBED-CC-PSMA-11的摄取量-时间曲线图(n＝3)；
如图15所示为本发明应用实施例2中，体外22RV1-FOLH1-oe细胞摄取实验分析[68Ga]Ga-AAZTA-NI-PSMA、[68Ga]Ga-DOTA-NI-PSMA、[68Ga]Ga-HBED-CC-NI-PSMA和[68Ga]Ga-HBED-CC-PSMA-11与前列腺特异型膜抗原受体的特异性结合图(n＝3)。
由体外细胞摄取实验结果可知，22RV1-FOLH1-oe细胞与[68Ga]Ga-AAZTA-NI-PSMA、[68Ga]Ga-DOTA-NI-PSMA、[68Ga]Ga-HBED-CC-NI-PSMA和[68Ga]Ga-HBED-CC-PSMA-11，随着孵育时间的延长，摄取先增加后降低，其中[68Ga]Ga-HBED-CC-NI-PSMA在多个时间点的细胞摄取量均显著高于FDA已经批准的[68Ga]Ga-HBED-CC-PSMA-11。在过量非放射性标记的PSMA-11存在下，放射性金属配合物的摄取显著降低，表明22RV1-FOLH1-oe细胞对配合物的摄取均为特异性摄取，PSMA与本发明的放射性金属配合物结合为特异性结合。
应用实施例3
[68Ga]Ga-AAZTA-NI-PSMA-093体外22RV1-FOLH1-oe细胞摄取：
将22RV1-FOLH1-oe细胞配制成1×105个/mL的细胞悬液，分别取500μL接种至3个12孔板中，各向组孔板中分别加入37KBq的[68Ga]Ga-AAZTA-NI-PSMA-093和[68Ga]Ga-HBED-CC-PSMA-11溶液，在37℃下，在各组孵育的第15、30、60、90和120分钟，使用PBS溶液终止其摄取，使用1M NaOH裂解细胞，使用滤纸吸取细胞裂解液塞入塑料试管中测定放射性计数；使用过量未标记的PSMA-11在60分钟时，阻断细胞摄取，孵育结束后，使用PBS溶液终止其摄取，使用1M NaOH裂解细胞，使用滤纸吸取细胞裂解液塞入塑料试管中测定放射性计数。
如图16所示为本发明应用实施例2中，体外22RV1-FOLH1-oe细胞摄取[68Ga]Ga-AAZTA-NI-PSMA-093和[68Ga]Ga-HBED-CC-PSMA-11的摄取量-时间曲线图(n＝3)；
如图17所示为本发明应用实施例2中，体外22RV1-FOLH1-oe细胞摄取实验分析[68Ga]Ga-AAZTA-NI-PSMA-093和[68Ga]Ga-HBED-CC-PSMA-11与前列腺特异型膜抗原受体的特异性结合图(n＝3)。
由体外细胞摄取实验结果可知，22RV1-FOLH1-oe细胞与[68Ga]Ga-HBED-CC-PSMA-11和[68Ga]Ga-AAZTA-NI-PSMA-093，随着孵育时间的延长，摄取先增加后降低，其中[68Ga]Ga-AAZTA-NI-PSMA-093在多个时间点的细胞摄取量均显著高于FDA已经批准的[68Ga]Ga-HBED-CC-PSMA-11。在过量非放射性标记的PSMA-11存在下，放射性金属配合物的摄取显著降低，表明22RV1-FOLH1-oe细胞对配合物的摄取均为特异性摄取，PSMA与本发明的放射性金属配合物结合为特异性结合。
应用实施例4
[68Ga]Ga-NI-HBED-CC-PSMA-11和[68Ga]Ga-NI-HBED-CC-PSMA-093体外22RV1-FOLH1-oe细胞摄取：
将22RV1-FOLH1-oe细胞配制成2×105个/mL的细胞悬液，分别取500μL接种至6个12孔板中，各向组孔板中分别加入37KBq的[68Ga]Ga-HBED-CC-PSMA-11、[68Ga]Ga-NI-HBED-CC-PSMA-11、[68Ga]Ga-HBED-CC-PSMA-093和[68Ga]Ga-NI-HBED-CC-PSMA-093溶液，在37℃下，在各组孵育的第15、30、60、90和120分钟，使用PBS溶液终止其摄取，使用1M NaOH裂解细胞，使用滤纸吸取细胞裂解液塞入塑料试管中测定放射性计数；使用过量未标记的PSMA-11在60分钟时，阻断细胞摄取，孵育结束后，使用PBS溶液终止其摄取，使用1M NaOH裂解细胞，使用滤纸吸取细胞裂解液塞入塑料试管中测定放射性计数。
如图18所示为本发明应用实施例2中，体外22RV1-FOLH1-oe细胞摄取[68Ga]Ga-HBED-CC-PSMA-11、[68Ga]Ga-NI-HBED-CC-PSMA-11、[68Ga]Ga-HBED-CC-PSMA-093和[68Ga]Ga-NI-HBED-CC-PSMA-093的摄取量-时间曲线图(n＝3)；
如图19所示为本发明应用实施例2中，体外22RV1-FOLH1-oe细胞摄取实验分析[68Ga]Ga-HBED-CC-PSMA-11、[68Ga]Ga-NI-HBED-CC-PSMA-11、[68Ga]Ga-HBED-CC-PSMA-093和[68Ga]Ga-NI-HBED-CC-PSMA-093与前列腺特异型膜抗原受体的特异性结合图(n＝3)。
由体外细胞摄取实验结果可知，22RV1-FOLH1-oe细胞与[68Ga]Ga-HBED-CC-PSMA-11、[68Ga]Ga-NI-HBED-CC-PSMA-11、[68Ga]Ga-HBED-CC-PSMA-093和[68Ga]Ga-NI-HBED-CC-PSMA-093，随着孵育时间的延长，摄取逐渐增加，其中[68Ga]Ga-HBED-CC-PSMA-093在各个时间点的细胞摄取量均显著高于其它放射性金属配合物。在过量非放射性标记的PSMA-11存在下，放射性金属配合物的摄取显著降低，表明22RV1-FOLH1-oe细胞对配合物的摄取均为特异性摄取，PSMA与本发明的放射性金属配合物结合为特异性结合。
本发明含有硝基芳香杂环基团的靶向前列腺特异型膜抗原放射性金属配合物放射性配体，含有不同的螯合剂，能与当下几乎所有临床用放射性诊疗金属核素螯合，N,N’双[2-羟基5-(羧乙基)苄基]乙二胺-N,N’二乙酸(HBED-CC)能与Ga3+的热力学稳定常数高(logKML：38.5)，配位所需能量低，因此，[68Ga]Ga-HBED-CC的标记快速高效；1,4,7,10-四氮杂环十二烷-1,4,7,10-四羧酸(DOTA)和2,2’-(4,10-双羧甲基-1,4,7,10-四氮杂环十二烷-1,7-二基)二戊二酸(DOTAGA2)和2,2’-(6-(双羧甲基)氨基)-6-(4-羧丁基)-1,4-二氮杂环庚烷-1,4-二乙酸(AAZTA)能够实现多种医用放射性金属离子的标记，其中包括发射β+射线用于诊断的68Ga、[18F]AlF、44Sc和64Cu等核素；发射β-射线用于治疗的177Lu和90Y等核素；发射α射线用于治疗的225Ac和212/213Bi等核素。其中相比于DOTA，AAZTA能在较温和的条件下实现金属核素的标记。
本发明含有硝基芳香杂环基团的靶向前列腺特异型膜抗原放射性金属配合物，含有靶向前列腺特异性膜抗原的Lys-CO-Glu结构，能够与过表达前列腺特异性膜抗原的肿瘤细胞结合，并与前列腺特异型膜抗原受体共同被内化至细胞内，硝基芳香杂环基团能够增强配合物在肿瘤细胞内的滞留。
本发明中[68Ga]Ga-NI-HBED-CC-PSMA-093、[68Ga]Ga-AAZTA-NI-PSMA-093和[68Ga]Ga-HBED-CC-NI-PSMA在前列腺特异型膜抗原阳性细胞摄取显著高于已经被FDA批准的[68Ga]Ga-HBED-CC-PSMA-11。
本发明含有硝基芳香杂环基团的靶向前列腺特异型膜抗原放射性金属配体，能够实现多种放射性诊疗核素的标记，标记显像核素用作显像放射性金属配体能够得到高成像对比度的显像图；标记治疗核素用作放射性核素治疗药物能够增加药物在肿瘤部位的滞留，改善治疗效果，因此，本发明的含有硝基芳香杂环基团的靶向前列腺特异型膜抗原放射性金属配体能够更好的实现前列腺特异型膜抗原受体阳性肿瘤的诊疗一体化。
以上所述，仅为本发明的较佳实施例而已，故不能依此限定本发明实施的范围，即依本发明专利范围及说明书内容所作的等效变化与修饰，皆应仍属本发明涵盖的范围内。
Claims (10)
- 一种含硝基芳香杂环基团的PSMA靶向放射性金属配体，其通式如式Ⅰ-1所示：
其中，Chelator1为双功能螯合剂结构，选自以下任意一种：
R1为硝基芳香杂环基团，选自以下任意一种：
L1为Chelator1和PSMA靶向基团之间的连接基团，选自以下任意一种：
L2为Chelator1和R1基团之间的连接基团，选自以下任意一种
其中n取0至6的整数。 - 一种含硝基芳香杂环基团的PSMA靶向放射性金属配体，其通式如式Ⅱ-1所示：
其中，Chelator2为螯合基团或螯合放射性核素的螯合结构，选自以下任意一种：
R2为硝基芳香杂环基团，选自以下任意一种：
L3为Chelator2和PSMA靶向基团之间的连接基团，选自以下任意一种：
L4为Chelator2和R2基团之间的连接基团，选自以下任意一种：
其中，n取0至6的整数。 - 一种含硝基芳香杂环基团的PSMA靶向放射性金属配合物，其通式如式Ⅰ-2所示：
其中，Chelator1为螯合放射性核素的螯合结构，选自以下任意一种：
其中，M包括但不限于68Ga、18F-AlF、177Lu、90Y、44Sc、225Ac、212Pb或213Bi；R1为硝基芳香杂环基团，选自以下任意一种：
L1为Chelator1和PSMA靶向基团之间的连接基团，选自以下任意一种：
L2为Chelator1和R1基团之间的连接基团，选自以下任意一种
其中，n取0至6的整数。 - 一种含硝基芳香杂环基团的PSMA靶向放射性金属配合物，其通式如式Ⅱ-2所示：
其中，Chelator2为螯合基团或螯合放射性核素的螯合结构，选自以下任意一种：
其中，M包括但不限于68Ga、18F-AlF、177Lu、90Y、44Sc、225Ac、212Pb或213Bi；R2为硝基芳香杂环基团，选自以下任意一种：
L3为Chelator2和PSMA靶向基团之间的连接基团，选自以下任意一种：
L4为Chelator2和R2基团之间的连接基团，选自以下任意一种：
其中，n取0至6的整数。 - 权利要求1或2所述含硝基芳香杂环基团的PSMA靶向放射性金属配体，其具体结构如下：
- 如权利要求3或4所述含硝基芳香杂环基团的PSMA靶向放射性金属配合物，其具体结构如下：
- 如权利要求1所述含硝基芳香杂环基团的PSMA靶向放射性金属配体的制备方法，其步骤如下：(1)将三光气溶于二氯甲烷中，将溶于二氯甲烷的N(ε)-苄氧羰基-L-赖氨酸叔丁酯盐酸盐(H-Lys(Z)-Ot-Bu HCl)和三乙胺缓慢滴加至上述溶液中，将溶于二氯甲烷的L-谷氨酸二叔丁基酯盐酸盐和三乙胺缓慢滴加至上述溶液中，反应液室温下搅拌反应，减压蒸馏，使用硅胶柱色谱纯化(石油醚/乙酸乙酯＝1/1，v/v)，得到无色油状产物，将无色油状产物溶于四氢呋喃中，加入10％Pd/C，混合物于氢气气氛中室温下搅拌反应，所得反应液使用硅藻土抽滤，滤液减压旋蒸，除去溶剂，得到棕色油状化合物Lys(t-Bu)-CO-Glu(t-Bu)2，将Lys(t-Bu)-CO-Glu(t-Bu)2与Cbz-L1-NH2溶于无水DMF，冰浴下加入2-(7-偶氮苯并三氮唑)-N,N,N',N'-四甲基脲六氟磷酸酯和N,N’-二异丙基乙胺，室温反应，过夜分离，纯化，得到淡黄色油状化合物，将所得的淡黄色油状化合物溶于甲醇，加入Pd/C粉末，氢气气氛下还原，过夜，得到NH2-L1-Lys(t-Bu)-CO-Glu(t-Bu)2；(2)将(S)-4-((((9H-芴-9-基)甲氧基)羰基)氨基)-5-(叔丁氧基)-5-氧代戊酸溶于超干N,N-二甲基甲酰胺中，冰浴下加入2-(7-偶氮苯并三氮唑)-N,N,N',N'-四甲基脲六氟磷酸酯和N,N’-二异丙基乙胺，冰浴搅拌，随后加入R1-L2-NH2，反应液于室温搅拌，过夜，反应液用乙酸乙酯和饱和食盐水洗涤，收集有机相并用无水硫酸钠干燥，过滤，除掉无水硫酸钠，滤液减压旋蒸，除去溶剂后，通过硅胶柱色谱纯化(二氯甲烷/甲醇/氨水，v/v/v＝25/1/0.1)，得到淡黄色固体，将得到的淡黄色固体溶于三氟乙酸中，室温搅拌，减压蒸馏，得到淡黄色固体化合，将得到淡黄色固体化合溶于超干N,N-二甲基甲酰胺中，冰浴下加入2-(7-偶氮苯并三氮唑)-N,N,N',N'-四甲基脲六氟磷酸酯和N,N’-二异丙基乙胺，冰浴搅拌，将溶于超干N,N-二甲基甲酰胺的NH2-L1-Lys(t-Bu)-CO-Glu(t-Bu)2加入上述反应液，室温反应，过夜，反应液用乙酸乙酯和饱和食盐水洗涤，收集有机相并用无水硫酸钠干燥，过滤，除掉无水硫酸钠，滤液减压旋蒸，除去溶剂，剩余物通过快速纯化色谱仪纯化(二氯甲烷/甲醇/氨水，v/v/v＝15/1/0.1)，得到淡黄色固体状化合物，将得到的淡黄色固体状化合物溶于二氯甲烷中，逐滴加入二乙胺，室温搅拌，减压旋蒸，除去溶剂，得到R1-L2-NH-L1-Lys(t-Bu)-CO-Glu(t-Bu)2；(3)将螯合剂HBED-CC、AAZTA、DOTA或NOTA溶于无水DMF，冰浴下加入2-(7-偶氮苯并三氮唑)-N,N,N',N'-四甲基脲六氟磷酸酯和N,N’-二异丙基乙胺冰浴搅拌，随后加入步骤(2)所得的R1-L2-NH-L1-Lys(t-Bu)-CO-Glu(t-Bu)2，室温搅拌，过夜，经过硅胶柱色谱纯化，得到淡黄色油状液体R1-L2-NH-L1(chelator1)-Lys(t-Bu)-CO-Glu(t-Bu)2，将得到的R1-L2-NH-L1(chelator1)-Lys(t-Bu)-CO-Glu(t-Bu)2溶于三氟乙酸，室温搅拌，减压蒸馏，除去溶剂，经半制备HPLC纯化，得到如结构Ⅰ-1所示的标记配体R1-L2-NH-L1(chelator1)-Lys-CO-Glu。
- 如权利要求2所述含硝基芳香杂环基团的PSMA靶向放射性金属配体的制备方法，其步骤如下：(1)将三光气溶于二氯甲烷中，将溶于二氯甲烷的N(ε)-苄氧羰基-L-赖氨酸叔丁酯盐酸盐(H-Lys(Z)-Ot-Bu HCl)和三乙胺缓慢滴加至上述溶液中，将溶于二氯甲烷的L-谷氨酸二叔丁基酯盐酸盐和三乙胺缓慢滴加至上述溶液中，反应液室温下搅拌反应，减压蒸馏，使用硅胶柱色谱纯化(石油醚/乙酸乙酯＝1/1，v/v)，得到无色油状产物，将无色油状产物溶于四氢呋喃中，加入10％Pd/C，混合物于氢气气氛中室温下搅拌反应，，所得反应液使用硅藻土抽滤，滤液减压旋蒸，除去溶剂，得到棕色油状化合物Lys(t-Bu)-CO-Glu(t-Bu)2，将Lys(t-Bu)-CO-Glu(t-Bu)2与Cbz-L3-NH2溶于无水DMF，冰浴下加入2-(7-偶氮苯并三氮唑)-N,N,N',N'-四甲基脲六氟磷酸酯和N,N’-二异丙基乙胺，室温反应，过夜，分离，纯化，得到淡黄色油状化合物，将所得的淡黄色油状化合物溶于甲醇，加入Pd/C粉末，氢气气氛下还原过夜，得到NH2-L3-Lys(t-Bu)-CO-Glu(t-Bu)2；(2)将螯合剂HBED-CC、AAZTA、DOTA或NOTA溶于无水DMF，冰浴下加入2-(7-偶氮苯并三氮唑)-N,N,N',N'-四甲基脲六氟磷酸酯和N,N’-二异丙基乙胺冰浴搅拌，随后加入R2-L4-NH2，反应液于室温搅拌，过夜，反应液用乙酸乙酯和饱和食盐水洗涤，收集有机相并用无水硫酸钠干燥，过滤， 除掉无水硫酸钠，滤液减压旋蒸，除去溶剂后，通过硅胶柱色谱纯化(二氯甲烷/甲醇/氨水，v/v/v＝90/10/0.1)，得到淡黄色固体R2-L4-NH-chelator2，将所得的淡黄色固体R2-L4-NH-(chelator2)溶于无水DMF，冰浴下加入2-(7-偶氮苯并三氮唑)-N,N,N',N'-四甲基脲六氟磷酸酯和N,N’-二异丙基乙胺，冰浴搅拌，随后加入步骤(1)所得的NH2-L3-Lys(t-Bu)-CO-Glu(t-Bu)2，随后加入R2-L4-NH2，反应液于室温搅拌，过夜，反应液用乙酸乙酯和饱和食盐水洗涤，收集有机相并用无水硫酸钠干燥，过滤，除掉无水硫酸钠，滤液减压旋蒸，去除溶剂后，通过硅胶柱色谱纯化(二氯甲烷/甲醇/氨水，v/v/v＝90/10/0.1)，得到淡油状液体R2-L4-NH-chelator2-NH-L3-Lys(t-Bu)-CO-Glu(t-Bu)2，将得到的R2-L4-NH-chelator2-NH-L3-Lys(t-Bu)-CO-Glu(t-Bu)2溶于三氟乙酸，室温搅拌，减压蒸馏，除去溶剂，经半制备HPLC纯化，得到如结构Ⅰ-2所示的标记配体R2-L4-NH-chelator2-NH-L3-Lys-CO-Glu。
- 如权利要求3所述含硝基芳香杂环基团的PSMA靶向放射性金属配合物的制备方法，其步骤如下：在权利要求7的基础上，增加如下步骤：将步骤(3)所得标记配体R1-L2-NH-L1(chelator1)-Lys-CO-Glu溶于醋酸钠缓冲溶液，向溶液中加入[68Ga]GaCl3或[177Lu]LuCl3含有放射性核素的溶液，加热条件下反应5-15min，得到相应的如结构Ⅱ-1所示的放射性金属配合物。
- 如权利要求4所述含硝基芳香杂环基团的PSMA靶向放射性金属配合物的制备方法，其步骤如下：在权利要求8的基础上，增加如下步骤：将步骤(3)所得标记配体R2-L4-NH-chelator2-NH-L3-Lys-CO-Glu溶于醋酸钠缓冲溶液，向溶液中加入[68Ga]GaCl3或[177Lu]LuCl3含有放射性核素的溶液，加热条件下反应5-15min，得到相应的如结构Ⅱ-2所示的放射性金属配合物。
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202380008288.4A CN116507630A (zh) | 2023-02-14 | 2023-02-14 | 含硝基芳香杂环基团的psma靶向放射性金属配合物及其制备 |
| PCT/CN2023/075960 WO2023231452A1 (zh) | 2023-02-14 | 2023-02-14 | 含硝基芳香杂环基团的psma靶向放射性金属配合物及其制备 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2023/075960 WO2023231452A1 (zh) | 2023-02-14 | 2023-02-14 | 含硝基芳香杂环基团的psma靶向放射性金属配合物及其制备 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2023231452A1 true WO2023231452A1 (zh) | 2023-12-07 |
Family
ID=87327130
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/CN2023/075960 WO2023231452A1 (zh) | 2023-02-14 | 2023-02-14 | 含硝基芳香杂环基团的psma靶向放射性金属配合物及其制备 |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN116507630A (zh) |
| WO (1) | WO2023231452A1 (zh) |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130034494A1 (en) * | 2011-08-05 | 2013-02-07 | Molecular Insight Pharmaceuticals | Radiolabeled prostate specific membrane antigen inhibitors |
| US20160067361A1 (en) * | 2014-09-08 | 2016-03-10 | Molecular Insight Pharmaceuticals, Inc. | Organ protection in psma-targeted radionuclide therapy of prostate cancer |
| US20160304555A1 (en) * | 2011-08-22 | 2016-10-20 | Eric Wang | PSMA Imaging Agents |
| CN108541302A (zh) * | 2015-12-31 | 2018-09-14 | 五制药股份有限公司 | 用于成像和治疗的尿素基前列腺特异性膜抗原(psma)抑制剂 |
| CN112574280A (zh) * | 2020-12-21 | 2021-03-30 | 北京大学第一医院 | 一种双酶体系探针及其应用 |
| CN114096264A (zh) * | 2019-05-20 | 2022-02-25 | 因多塞特股份有限公司 | 制备psma缀合物的方法 |
| CN114984255A (zh) * | 2022-05-31 | 2022-09-02 | 苏州大学 | 一种放射性核素标记的PSMA-αvβ3双靶点偶联体及其应用 |
-
2023
- 2023-02-14 WO PCT/CN2023/075960 patent/WO2023231452A1/zh unknown
- 2023-02-14 CN CN202380008288.4A patent/CN116507630A/zh active Pending
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130034494A1 (en) * | 2011-08-05 | 2013-02-07 | Molecular Insight Pharmaceuticals | Radiolabeled prostate specific membrane antigen inhibitors |
| US20160304555A1 (en) * | 2011-08-22 | 2016-10-20 | Eric Wang | PSMA Imaging Agents |
| US20160067361A1 (en) * | 2014-09-08 | 2016-03-10 | Molecular Insight Pharmaceuticals, Inc. | Organ protection in psma-targeted radionuclide therapy of prostate cancer |
| CN108541302A (zh) * | 2015-12-31 | 2018-09-14 | 五制药股份有限公司 | 用于成像和治疗的尿素基前列腺特异性膜抗原(psma)抑制剂 |
| CN114096264A (zh) * | 2019-05-20 | 2022-02-25 | 因多塞特股份有限公司 | 制备psma缀合物的方法 |
| CN112574280A (zh) * | 2020-12-21 | 2021-03-30 | 北京大学第一医院 | 一种双酶体系探针及其应用 |
| CN114984255A (zh) * | 2022-05-31 | 2022-09-02 | 苏州大学 | 一种放射性核素标记的PSMA-αvβ3双靶点偶联体及其应用 |
Non-Patent Citations (2)
| Title |
|---|
| KWON YOUNG-DO ET AL.: "Novel multifunctional 18F-labelled PET tracer with prostate-sepcific membrane antigen-targeting and hypoxia-sensitive moieties", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, vol. 189, 25 January 2020 (2020-01-25), XP086046624, ISSN: 0223-5234, DOI: 10.1016/j.ejmech.2020.112099 * |
| KWON YOUNG-DO ET AL.: "Synthesis and Evaluation of Multifunctional Fluorescent Inhibitors with Synergistic Interaction of Prostate-Specific Membrane Antigen and Hypoxia for Prosteta Cancer", BIOCONJUGATE CHEM., vol. 30, no. 1, 28 November 2018 (2018-11-28), XP055945984, ISSN: 1043-1802, DOI: 10.1021/acs.bioconjchem.8b00767 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN116507630A (zh) | 2023-07-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7442020B2 (ja) | 前立腺特異的膜抗原を標的とする化合物及びその調製方法と応用 | |
| KR101314460B1 (ko) | Ｒｇｄ-함유 펩티드의 방사성 표지된 접합체 및클릭-화학을 통한 그의 제조 방법 | |
| CN111065646B (zh) | 放射性药物 | |
| JPH075527B2 (ja) | 二官能性ｄｔｐａ型リガンド | |
| CN115286697B (zh) | 一种双重靶向化合物及其制备方法和应用 | |
| KR101106433B1 (ko) | 암 조직의 타겟팅을 위한 마크로사이클릭 아미노산 계열의 유도체 및 그의 방사성 또는 비방사성 금속 표지화합물 | |
| CA3136979A1 (en) | Radiolabelled compounds for diagnosis or treatment of prostate-spe cific membrane antigen-expressing cancer | |
| CN115260160A (zh) | 一种靶向成纤维细胞活化蛋白fap的化合物及其制备方法和应用 | |
| Makris et al. | Synthesis and evaluation of fac-[99mTc/Re (CO) 3]+ complexes with a new (N, S, N) bifunctional chelating agent: The first example of a fac-[Re (CO) 3 (N, S, N-sst2-ANT)] complex bearing a somatostatin receptor antagonist peptide | |
| WO2024067531A1 (zh) | 一种成纤维细胞活化蛋白FAP和整合素αvβ3双重靶向化合物及其制备方法和应用 | |
| WO2023231452A1 (zh) | 含硝基芳香杂环基团的psma靶向放射性金属配合物及其制备 | |
| CA2421182A1 (en) | Conjugates of antioxidants with metal chelating ligands for use in diagnostic and therapeutic applications | |
| CN115433261B (zh) | 一种rgd二聚体化合物及其制备方法和应用 | |
| JP6410339B2 (ja) | 放射性核種標識オクトレオチド誘導体 | |
| CN116751259A (zh) | 一种成纤维细胞活化蛋白FAP和整合素αvβ3双重靶向化合物及其制备方法 | |
| EP4263509A1 (en) | Radiolabeled compounds targeting the prostate-specific membrane antigen | |
| US20220072165A1 (en) | Radiodrug for diagnostic/therapeutic use in nuclear medicine and radio-guided medicine | |
| WO2024021556A1 (zh) | 一种靶向前列腺特异性膜抗原的放射性金属配合物及其标记配体 | |
| CN115368342B (zh) | 成纤维细胞活性蛋白抑制剂、其放射性核素标记物及制备方法和应用 | |
| AU2021427618B2 (en) | Truncated evans blue modified fibroblast activation protein inhibitor, preparation method therefor, and application thereof | |
| TW202419460A (zh) | 一種rgd二聚體化合物及其製備方法和應用 | |
| KR20240045256A (ko) | 가교기로서 킬레이트기를 포함하는 리간드 화합물 | |
| EP3096799B1 (en) | Labeled molecular agents for imaging cystine/glutamate antiporter | |
| CN117279930A (zh) | 三官能化合物和其用途 | |
| CN118084701A (zh) | 酪氨酸衍生物及其制备方法、制备原料和应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23814651 Country of ref document: EP Kind code of ref document: A1 |